Academy for Educational Development
1825 Connecticut Avenue, N.W.
Academy Hall, 8th Floor
Washington, D.C.
Dr. Angell, in a previous session, made the
distinction between the scientific principles underlying the methodology and
scientific methodologies. I think this is very important. We can say
with confidence that we understand the underlying principles, but I don't think
we can say that there aren't new methods out there that we need to explore.
Unfortunately, the authors rarely do provide
us with these innovative methods, and this brings me to my recommendations to
the Commission. There is a need for more academic departments and research
positions, at post-doctoral level, to attract the brightest and best into the
field.
There is also a need for more research money
for practitioner training schools, as they are the ones with the knowledge and
insights needed to develop appropriate methodologies. There is a need to
expand the range of acceptable models of quality clinical research, beyond the
formulaic, large clinical trial protocols, while retaining integrity and
authority, and adhering to those principles previously mentioned.
There is also a particular need for
sponsorship from independent funding sources that will encourage innovative and
imaginative but rigorous research.
I was speaking to a colleague a couple of
days ago. He is from Vienna. Just as an example of what I am talking
about, there are a lot of interesting groups in Europe who are doing all sorts
of experimental science and trials of different methodologies. This one
group was testing out a diagnostic treatment device, rather like a vega device
for testing of allergies.
You plug this machine in, and you put in
various substances to which people might be allergic, and then apply part of
this diagnostic technique to the patients. Then one of them said, hey,
what happens if you unplug it? So they unplugged it, and it still
worked. Then the next question, of course, was, well, how far away does it
have to be and still work, and they found that it could be as far as five feet
away and it still worked.
Well, what I am saying here is, you do need
people to ask these simple but dramatic questions that raise all sorts of other
interesting issues.
DR. GORDON: Time is up.
MS. WOOTTON: Yes. I have left
the statistics. I don't know whether you want me to say those very, very
quickly.
When the journal changed from quarterly to
bi-monthly at the beginning of '99, more libraries subscribed. Currently,
60 percent of our subscriptions are medical or biomedical school libraries, and
libraries in research institutions. The other 40 percent of individual
subscribers are equally divided between clinicians or practitioners,
researchers, and others. Thank you.
DR. GORDON: Thank you.
Phil Fontanarosa.
Presenter: Phil B. Fontanarosa,
M.D.
DR. FONTANAROSA: Dr. Gordon,
distinguished members of the White House Commission, thank you very much for the
opportunity to participate in this meeting and to provide information on the
topic of publication of complementary and alternative medicine, CAM, research
results and peer-reviewed medical journals.
My remarks are intended to address several
of the questions you provided by discussing, briefly, three questions relevant
to peer-reviewed general medical journals, and from the perspective of my role
as executive deputy editor of JAMA.
First: Why should medical journals consider
publishing research on complementary and alternative medicine?
Well, as you all well know, all too well, of
course, the use of complementary and alternative medicine and visits to
alternative medicine practitioners have increased dramatically, along with
marked increases in expenditures for these therapies and increasingly prevalent
third party reimbursement for these therapies.
At academic medical centers, there has been
increased interest among medical students, residents, and faculty members in
gaining knowledge about alternative therapies. Now, educational
opportunities for CAM have been added to the curriculum in many medical schools.
In addition, there have been significant
increases in federal funding for national academic centers dedicated to CAM
research, along with increased funding from government and from industry to
examine CAM therapies.
Yet, despite the increasing interest in CAM,
high-quality scientific evidence that clearly establishes the safety and
efficacy, or a lack thereof, for many of the widely used CAM interventions is
lacking. Consequently, physicians have traditionally viewed CAM in
general, and most practices contained therein, with skepticism and a degree of
mistrust, I would say. Nonetheless, many patients use CAM therapies along
with their conventional medical therapies.
I believe that physicians should be the
health professionals who are aware of and responsible for coordinating all
medical care for their patients. Accordingly, physicians require reliable
information on CAM to understand the complex interplay of CAM therapies and
conventional therapies to be prepared to serve as resources for their patients,
and to be comfortable answering their patients' questions about CAM, and most
important, to provide evidence-based guidance and advice about various CAM
therapies.
Ideally, this information should be based on
critically evaluated methodologically rigorous and scientifically valid articles
published in reputable journals, rather than on anecdotal reports, unfounded
opinion, or unproven theories regarding CAM therapies.
To be relevant to readers, medical journals
must respond to trends in medical science, react to trends among the public
regarding medical therapies, and also must serve the needs of their
readers. In a 1997 survey, physician readers of JAMA ranked alternative
medicine as the seventh most important topic of 70 topics we presented them with
for the journal to address. The Editorial Board and editorial staff, after
much debate and deliberation, ranked alternative medicine in the top three
subjects to address for that year.
Thus, JAMA and the nine Archives journals
published by the AMA, The Archives of Internal Medicine, Archives of Pediatrics
and Adolescent Medicine, and so on, planned and developed an initiative to
objectively assess various CAM therapies. We published coordinated theme
issues, largely devoted to CAM topics, November of 1998.
Through this initiative, we provided more
than 80 articles on CAM topics to the peer-reviewed biomedical literature.
I was responsible for planning, coordinating, and editing this issue of JAMA
that we published on complementary and alternative medicine, and also helped to
coordinate efforts with the Archives journals.
The second issue: How do peer-reviewed
journals evaluate research on complementary and alternative medicine?
I believe peer-reviewed journals should be
willing to consider papers on virtually any topic relevant to the practice of
medicine, medical research, and relevant to their physician readers. Most
research papers on CAM should not be rejected out of hand, simply based on the
topic, but should receive an unbiased, objective editorial evaluation based on
assessment of the following: the scientific importance of the study; the
methodologic rigor with which the research is conducted; the novel contribution
to the existing literature; and the relevance of the study results for the
journal's readers.
Evaluation of the scientific qualities
should involve the same rigorous and critical appraisal used to assess studies
reporting research on conventional therapies and the accepted framework of
scientific evidence should and must prevail.
Some key aspects in the evaluation of CAM
research studies include assessment of whether the paper presents the following:
and explicit, focused research question; scientific or biologic plausibility;
defined target disease or condition; established and accepted rigorous research
methods, appropriate controls, for example; measurable, objectively assessed
endpoints, such as by blinded assessment; meaningful patient-centered outcomes;
information on adverse effects and safety data; and appropriate discussion of
the clinical context, public health importance, and study limitations.
The assessment of CAM research studies
frequently involves peer review. Peer review of these studies involves
selection of appropriate peer reviewers who have expertise in the research
methods and subject matter of the study. The goal is to obtain an
objective and unbiased evaluation of the research.
Reviewers are identified and selected in
several ways, but most commonly from a large database of reviewers we have at
JAMA. This database includes self-designated areas of expertise of the
reviewers, along with editors' ratings of the quality of the review. We
also frequently perform literature searches for individuals who have expertise
with the research topic under evaluation.
These peer reviewers serve as important
consultants. They provide the editors with information regarding the
context and the contribution of the study, in light of existing research, as
well as a critical appraisal of the research methods and statistical analyses.
Peer reviewers also provide recommendations
about the suitability of the study for publication in the journal, and
constructive, objective suggestions to improve the research report.
Comments of the peer reviewers are
considered very carefully in editorial decision-making about all research
papers, including CAM research. Physician reviewers are now available for
most topics evaluated in CAM research.
In general, decisions to publish CAM studies
in a general medical journal, like JAMA, for instance, involve assessment of the
quality of the research, the clinical applicability and importance of the
research, and the generalizability of the research findings.
An important consideration is the assessment
of the merits of the study compared with the information provided in the many
other papers submitted for consideration for publication. As you might
expect, in large-circulation, general medical journals, competition for space is
extremely keen, particularly keen, with a large number of submitted papers that
span the entire gamut of medical research, clinical care, and medical and
surgical specialties.
In 2000, the overall acceptance rate for all
manuscripts submitted to JAMA was about 10 percent, and for unsolicited
manuscripts, the acceptance rate was about 8 percent. With this
competition for space, reports of large-scale, high-quality, multi-center,
randomized trials, our highest level of evidence, on clinically important
topics, are more likely to receive priority for publication than are
single-center studies reporting intermediate or preliminary results about
specialized CAM therapies.
In fact, during the past year, of the
several studies that we published in JAMA on CAM therapies, most have been
randomized trials.
The third question I would like to address,
the final, is: What are some of the policy issues regarding publication of CAM
research in peer-reviewed journals?
In general, I would support Dr. Campion's
policy recommendations, and in addition, would offer several others regarding
publication of CAM research in peer-reviewed journals.
Carefully conducted, high-quality, credible
research by established biomedical investigators is necessary to evaluate the
efficacy and safety of complementary and alternative medicine therapies.
However, until convincing evidence is available that demonstrates safety,
efficacy, and effectiveness of these interventions, the uncritical acceptance
and widespread application must stop.
With the recent increases in research
funding, the establishment of national centers for CAM research, future
publication of high-quality studies on CAM therapies should help to establish
the evidence base that supports or refutes the safety and efficacy of these many
therapies.
Complementary and alternative medicine
therapies that are shown to cause, or that are demonstrated to have no
beneficial effect should be abandoned. Decisions regarding the use of and
reimbursement for CAM therapies should be based on published evidence and proper
cost effectiveness analyses, rather than tradition, anecdotal reports,
testimonials, consumer interest, market demand, competition, or political
pressures.
Answering fundamental questions about CAM
therapies requires critical and objective assessment, using accepted standards
for scientific investigation and rigorous evaluation of scientific
evidence. Peer-reviewed medical journals provide one important mechanism
for such rigorous evaluation of CAM research, and for providing physicians with
reliable information about these diverse and complex therapies.
Dr. Gordon, members of the Commission, thank
you very much for the opportunity to present these perspectives on publication
of CAM research in peer-reviewed medical journals. I hope this information
is useful in your deliberations on complementary and alternative medicine
research policy. Thank you very much.
DR. GORDON: Thank you very much.
David Riley.
Presenter: David Riley, M.D.
DR. RILEY: First, I would like the
thank the Commission, Dr. Gordon and the other members of the Commission, for
inviting me here.
My name is David Riley. I am a
physician, board-certified in internal medicine and the editor-in-chief of the
Journal Alternative Therapies in Health and Medicine. We began publication
in 1995, and were indexed in 1996, and are in the National Library of Medicine.
We view ourselves as a forum for the
development of scientific information about the use of alternative therapies and
their role in preventing and treating disease, healing illness, and promoting
health. We don't endorse any particular methodology, but we promote the
rigorous evaluation of all therapies.
We publish a variety of disciplined inquiry
methods, focusing on high-quality scientific research, including randomized,
controlled trials, outcome studies, and case reports.
So you might ask the question, why do we
need a journal focusing on CAM, and also, is a journal focusing on CAM able to
be scientific. I think a recent letter to "Science" illustrates many of
these questions. It was entitled, "Where Is The Next Einstein?"
It was submitted with a score of signatures
from respected academics, including Nobel laureate, Sir Harry Kroto, who is a
chemist in England at Sussex, and Dudley Herschbach, a chemist at Harvard,
stating that, "All too often the academic research environment favors objectives
selected by consensus. Pioneers and consensus can be very poor
bedfellows. The vogue for expensive, collaborative projects leave little
space or money for alternative thinkers. Thinkers whose research may
appear initially irrelevant, but who may come up with stunning work."
I might also add that this letter was
rejected to the editors of "Science". We feel that our journal tries to
address this need, and provide a home for some promising and innovative
research.
Our journal is by paid subscription only,
and the readership consists, primarily, of conventionally licensed health care
providers, 60 percent physicians; the balance made up of nurses, other licensed
health care providers, naturopaths. It is interesting that the readership
is primarily conventional physicians.
I have some statistics here that I want to
go over, briefly, and then I will talk a little bit about the complexity of
reviewing articles in a peer-reviewed scientific journal devoted to CAM.
Eighty-seven percent of the original
research articles are rejected, 79 percent of brief reports are rejected, 73
percent of hypothesis articles, which is a new section, are rejected -- those
statistics could change -- and 64 percent of review articles are rejected.
We have taken an approach that we need a
variety of area in the journal to address different types of research. So
we have an Original Article section, which is devoted, primarily, to randomized,
controlled trials, although I would say, frankly, that we generally will not get
large, randomized, multi-center trials submitted to the journal. We have,
on occasion, and we have one in this issue. More commonly, we will get
smaller studies.
We also have brief reports. We also
have review articles, sometimes solicited. We also have some other
sections, too, that I think are critical. We have case reports, which are
beginning to lay the groundwork for future research that might be done, and I
think it is important to have these areas there.
We also have introduced a new section that
will start in July on research letters, because, frankly, one of our roles is to
educate people who are doing research, and to work with authors so that they can
begin to learn how to communicate, because if we are going to communicate with
the medical establishment, one of the principles is that you have the
communicate in their language, and their language is primarily the peer-reviewed
biomedical publication.
So a medical journal that is going to focus
on complementary and alternative medicine, by definition, is not designed just
for the specialists in a given field. They have their own forums for
communication amongst themselves. Our goal is to try to communicate the
results in complementary and alternative medicine with the biomedical
establishment.
I want to talk a little bit about the
difficulty of reviewing articles in complementary and alternative medicine,
because they can be considerable. If you look at a conventional medical
journal, particularly a specialty journal, there may be a lot of collegiality;
everybody knows everybody. The research areas are fairly well
defined. The unknowns are known. Frequently, the question becomes
one of statistics and methods.
Certainly, in our field, statistics and
methods are important. All articles that are submitted go through a
methodological review. One of our associate editors is a methodologist,
and we have several statisticians and methodologists on our editorial board that
we turn to regularly, probably too regularly. That is just the way it is.
We talked a lot about acupuncture research
here today. Let me take that as an example. If someone submits an
article on acupuncture, you need to know, is the author coming from a
five-elements school; do they do traditional Chinese medicine; is this a medical
acupuncture community; are they doing Korean hand acupuncture. You name
it, there are a of different areas that you need to know.
So not only do you need to find experts in
methodology in the given area, but you also have to find an expert in that given
therapy. So you have to pay particular attention. We have run into
issues where, all of a sudden, we realized these two groups that are actually
subgroups of a therapy, may not agree with other people about how these things
are practiced.
So it can be quite challenging. Most
articles that come in, the original research articles, go through at least
revisions, which means there is a review at the end of each revision, because
they can be quite complex. There may be as many as four or five, and I
have had even six reviewers on some articles. Consequently, one of the
problems with that is it can delay publication significantly, because each
review process, you kind of start anew each time.
So publishing a biomedical journal that is
peer-reviewed and indexed, and focusing on complementary medicine is quite
challenging, but I also think it is quite necessary, because we need to begin to
lay the groundwork for how to communicate with the biomedical
establishment. I also think we need to have a way to begin to publish
other kinds of studies.
The conventional medical establishment is
much more mature than the complementary and alternative medicine
community. The biomedical model is known. It is taken for
granted. It is taught in all medical schools. In complementary and
alternative medicine, there are multiple models present.
Just as the randomized, controlled trial is
the current best tool we have for investigating a particular type of decision,
it is implemented against a background of information, knowledge, and
understanding that may not be quite as widespread in complementary and
alternative medicine.
I would use the analogy, it is similar to
looking at a mural on a wall of building, if you would imagine, with a
telescope. You might get very finely developed information about a very
small part of that mural, but you won't understand the mural.
Many of the randomized, controlled trials
that are being done, it is difficult to evaluate the results, positive or
negative, because you may not actually be looking at an effective evaluation of
that treatment.
And so, I think this is a really challenging
time and opportunity to begin to develop an evidence profile for complementary
and alternative medicine, and to begin to stimulate the next generation of
research. Thank you.
DR. GORDON: Thank you, David.
Christine Laine.
Presenter:
Christine Laine, M.D.
DR. LAINE: I am Christine Laine and I
am the Senior Deputy Editor of Annals of Internal Medicine. I thank the
Commission for the opportunity to present Annals' perspective at this meeting.
A little bit of background about
Annals. Annals is a peer-reviewed biomedical journal that has been
published by the American College of Physicians since 1927. Our
circulation is over 100,000, making us the third largest U.S. general medical
journal, and the largest medical subspecialty journal, since our focus is on
internal medicine.
Our readers are largely internists, but not
all. Some may practice integrative medicine or prescribe CAM therapies
themselves, but almost all of them who are clinicians probably take care of
patients who seek CAM therapies as well as conventional medical therapies.
Our journal has a high impact factor.
We publish original research reviews, editorials, perspectives, and
guidelines. Aware of the prevalent and increasing use of CAM by people who
also seek care from internists, Annals believes strongly that high-quality
research and discourse concerning the effectiveness and the safety of commonly
used CAM therapies is of great relevance to our readership.
While the number of papers relating to CAM
submitted to Annals is increasing, the number remains quite small. In
preparation for this conference, I looked over the information on submitted
manuscripts from January 1999 through April of 2001. Of the, roughly,
6,000 papers submitted to our journal for consideration during that period, only
35 papers related to CAM therapies.
Consequently, we have been developing a
series of papers on CAM in close collaboration with two guest editors who are
expert in the area. This series will include somewhere between 15 and 20
papers, and will include a combination of original health services research,
critical reviews of the literature, and commentary on a variety of CAM-related
issues.
The papers submitted for this series will be
subject to Annals usual review process. Unfortunately, the series will not
include original research on specific CAM therapies. We do anticipate the
publication of the series will send out a signal that Annals is interested in
the topic and may stimulate investigators in the area to send their original
research reports to Annals.
When CAM papers are submitted to Annals,
they are subject to our usual rigorous review process. Unfortunately, many
of the papers concerning CAM have important methodological weaknesses, which
doesn't make them all that different than many of the papers that concern
conventional therapies.
We try to get reviewers that have expertise
in alternative medicine, as well as reviewers that have expertise in the
particular clinical condition under study. We have an electronic database
of about 10,000 reviewers, but fewer than 100 of the people in that database
admit to having expertise in CAM. So it is a challenge to get reviewers
with this expertise.
Let me tell you a little bit about what
happened to the 35 papers on CAM submitted to Annals between January '99 and
April of 2001. Two were ultimately published as full articles; one is the
letter to the editor; 31 were rejected; and one is in my briefcase to be
discussed at our Manuscript Conference tomorrow.
This represents an 8 percent acceptance
rate, which is not all that different from Annals' general acceptance rate,
which hovers somewhere between 10 and 14 percent, depending on the year.
The acceptance rate for the papers that have been invited to the series is
somewhat higher. We have a special commitment to working with authors
through many more rounds of revisions of those papers. Seventeen have been
submitted; nine are accepted; three have been reinvited after substantial
revision; three are currently under review; and two have been rejected.
Over recent decades, journals, like the
larger medical community, have become increasingly aware of the importance of
evidence-based medicine, the growth of large, clinical trials, advances in
statistical and analytic approaches, consensus guidelines such as the
consolidated standards of reporting trials, and consortia such as the Cochrane
Collaboration, are among the many factors contributing to the greater general
awareness of the importance of methodological rigor in studies of health care
interventions.
In previous times, the medical community
gave more weight to anecdotal evidence from case reports, case series, and
uncontrolled trials. In current times, these forms of investigation are
considered hypothesis-generating at best.
Unfortunately, much of the CAM-related
literature relies on methods that lack the rigor conventional medical journals
expect. This may be in part, and as we have heard today, because CAM
practitioners generally do not have the training and education in the
experimental process that has become part of the conventional medical education.
Many of the studies of CAM that authors
submit to our journal for consideration have important weaknesses such being
underpowered, uncontrolled, conducted in non-representative populations, or
having inadequate adjustment for potential confounders.
The manuscript that is in my briefcase is
one of these. It is an RCT of a common CAM therapy for a common medical
condition. It is funded by the NIH, HRSA, and industry. My prognosis
is that it is unlikely to make it into publication in Annals, despite having all
the trappings that elevate it. It has federal funding and it is a
randomized, controlled trial.
Part of the problems are that they used a
preparation that differs substantially from the ones that are in common use in
the community. They studied an atypical study population that doesn't,
probably, represent the larger community that uses this therapy; there is a lack
of objective outcome measures; and they have marginal statistical power.
Now, the study is reported as negative, but
when you look at it closely, it is not truly negative; it is inconclusive.
I think journals take the wrap for being unwilling to publish negative
trials. We have been very aware at Annals, and have one of our statistical
editors who has a particular interest in proving that there is no relationship
between two things.
So we very carefully look at negative
studies. Most of them are inconclusive, not negative. Our feeling
is, to do a study that is unlikely to give you a conclusive result is, at best,
a waste of resources, and, at worst, unethical.
Our suggestions are that we move beyond
anecdote and observation to higher levels of evidence; that there is a
particular focus on safety; another focus on the interactions between CAM
therapies and conventional therapies; and that the CAM therapies be subjected to
study with the rigor that the public has come to expect for conventional
therapies, realizing that innovative study design and methodologies may be
necessary, but that rigor can still exist. Thank you.
DR. GORDON: Thank you very much.
Arnold Relman.
Presenter:
Arnold Relman, M.D.
DR. RELMAN: Dr. Gordon and members of
the Commission, I cannot speak for the current policies of the New England
Journal of Medicine because I retired from the post of editor-in-chief nearly 10
years ago, after serving in that capacity for 14 years.
However, I was familiar with NEJM's policies
under its next two editors until the present editor assumed his post, a little
less than a year ago. Given those limitations, I can state confidently
that from July 1977, when I first became editor, until July 2000, when the
current editor took over, the New England Journal treated manuscripts dealing
with CAM in exactly the same manner it treated those concerned with more
conventional therapies, and that is the way it should be.
You have just heard Dr. Campion talk about
the philosophy of the current editorial leadership, and it appears to be
unchanged. You also heard a very forceful and very articulate statements
Drs. Fontanarosa and Laine, speaking for JAMA and Annals, supporting that idea.
Now, I emphasize this because one commonly
hears, particularly if you are an editor and you go around to meetings and so
on, you commonly hear the complaint that your journal, the New England Journal,
or some other leading peer-reviewed journal, is biased against manuscripts
dealing with CAM.
Now, all rejected authors tend to have a
certain amount of paranoia about their manuscripts and the reasons that they
were rejected. That is part of life. If you are an experienced
editor, as I was for decades, you expect this kind of paranoia and you know how
to deal with it, and that is by being absolutely sure you and your staff apply
the same standards to all would-be authors and all submissions, including those
from your mother, your brother, or from eminent and powerful people in your
field who may affect your future in medicine.
If you don't do that, if you apply different
standards, you are in deep trouble. The first advice I have always given
to new, young editors who used to come to me and ask me what philosophy do I
want to impart to them, is, one, always tell the truth because you can't
remember if you lie, and you will be caught sooner or later. Always tell
the truth, and always apply the same standards for the same reason. You
can't live with yourself, and your journal can't survive without that.
So I want to lay to rest the idea that CAM
manuscripts, just because they are about alternative medicine modalities, are
treated somehow differently. As far as I know, with the best peer-reviewed
journals, and you have heard a few representatives, they are treated the same.
Now, I don't know how many CAM manuscripts
we at the New England Journal received during those 23 years that I know
something about. We kept no special file, but there was certainly only a
handful of such submissions, and you hear now that there are still only a small
number. In any case, they were handled just like all the other submissions
and judged purely on their scientific merits and their suitability for our kind
of journal and our readership.
Now, that means that, yes, each editor and
each editorial staff has to decide what its readership will be interested in and
what will be useful and will determine the tone and the quality of that
particular journal.
But given the mounting interest and the
growing discussions about its credibility, an editor would be very ill advised
to do anything but give CAM submissions at least as much consideration as the
others. I have to tell you that, and I freely admitted my bias, I was
looking for good CAM manuscripts to publish. We got very few, and very few
of them met our publishing standards, but I tried very hard to find the best
that I could find. The fact that the journal only published a few,
primarily reflects the paucity of really good submissions.
Now, I do not have any statistical data on
the relative success rates of CAM papers versus other papers, but you heard some
data from Annals. I just don't know whether it is true of the New England
Journal or not, but certainly it was not any conscious editorial policy.
In any case, I think the issue is a fairly
straightforward one. I don't think you need to be a rocket scientist to
come to these conclusions. If CAM research is to have any credibility, it
will have to be submitted to the same range of peer-reviewed journals as the
more conventional manuscripts dealing with similar illnesses, and it will have
to pass the same kind of peer review. There cannot and there should not be
two standards of science. You have heard that before, nor should there be
two standards of peer review.
Unless CAM clinical investigators want to
stay outside the mainstream, they must play by the same scientific rules of
evidence and publish in the same journals.
So my advice to you is the following:
(1) Emphasize to your constituents and your
stakeholders -- that seems to be a popular word. I don't know what that
means, but you know what it means -- your stakeholders, emphasize to them that
the time has passed to make arguments based on unsubstantiated claims and
undocumented anecdotes; finished, enough of that, enough of the books that claim
miraculous cures with no documentation, enough of all the statements in public
meetings about marvelous results from a particular case without documentation.
I do not say that anecdotes are useless, and
I do not say that anecdotes are not used in ordinary, conventional medical
literature; they have been and they should be, but the anecdotes must be
documented. They must be documented.
(2) Encourage the submission of CAM
manuscripts to the most rigorously peer-reviewed journals over a wide spectrum,
not just to CAM journals but to all journals. Journals, after all, are not
ultimate arbiters of ultimate truth, neither the New England Journal, nor JAMA,
nor any other journal of which I am aware, was given by God insight into what
ultimate truth is and has the power and has the credibility to say that what we
publish is, for sure, true, and what we reject is, for sure, wrong. Not
so.
Journals do the best they can, as Ed Campion
said, they do the best they can. They try to sift out bad evidence from
better evidence, and they try to publish the best evidence on the most
interesting and the most relevant and important questions for their
readership. That opens the door for lots of journals, but they have to be
rigorous. They have to deal with evidence, quantitative, where possible,
objective evidence and documented data.
Finally, my advice to you is to remember
that quality, not number of publications, is the important thing. You
don't understand the quality until you read the whole paper, including the fine
print, and the methods, and the statistics, and the analysis, and the
discussion. You don't just read the summary, and you don't read somebody
else's opinion about what the journal said.
There is no substitute for evidence, and
there is no substitute for saying, well, what, actually, did they do; how did
they do it; and, what their data are. When you do that, you often come to
different conclusions than those that are generally bandied about.
For example, and I close with this, you
heard earlier this morning, that a meta-analysis of homeopathic medicine --
published, I think it was in Lancet. I read the paper, but I don't
remember, was it Lancet, or maybe BMJ -- a meta-analysis showed, beyond any
doubt, that homeopathy was effective.
Now, I can't quite remember what was in the
abstract, but I know very well what was in the paper, and if you read that
paper, it is very clear the data show, and the authors of the paper recognize
that the data show, that the best studies, the most rigorous studies, as judged
by the analysts, were inconclusive, and the ones that were statistically
significant were, by and large, much less rigorous. A slightly different
conclusion from what you heard a little while ago. Look at the evidence,
look at the data, and be guided by the evidence. Thank you very much.
Panel Discussion
DR. GORDON: Thank you. Thank
you, Dr. Relman.
Thank you all. It is a pleasure to see
all of you working so collaboratively with us in addressing these
questions. I feel there has been so much progress made in terms of the
dialogue with this field and the major journals.
There was only one thing I was disturbed
about, Dr. Relman. Forty years ago, when I entered Harvard Medical School,
I could have sworn they told me God dictated the contents of the New England
Journal every week.
[Laughter.]
DR. RELMAN: Well, you remember, Dr.
Gordon, and I was reminded of this just recently in a trip to Jordan, that Moses
was denied entrance to the Promised Land, and the New England Journal has not
yet gotten there.
[Laughter.]
DR. GORDON: Thank you for that
clarification.
I had one brief question. As I was
listening to a general consensus about the kinds of research that might be
published, it occurred to me that one of the places where there might be more
attention to CAM or integrative approaches, particularly in the mainstream
journals, because I know it is there in the CAM or integrative medicine
journals, is in some of the columns that are opinion columns, or the summaries
of the literature, or summaries of the clinical experience.
I wonder if you might respond to that,
because there has not been very much that I have read in the mainstream
journals.
DR. RELMAN: Is that addressed to me?
DR. GORDON: Well, you, Dr. Campion,
Dr. Laine, Dr. Fontanarosa.
DR. RELMAN: Well, most of the general
medical journals publish a variety of material. I think, as Dr.
Fontanarosa said, we publish not only original such articles, but also reviews
of the field, and commentary, and editorial opinion, and so on. Yes, of
course.
I remind you, The New England Journal
published the first study by David Eisenberg on the prevalence of alternative
medicine use, a very influential study. We didn't consider it as an
original research article in the usual sense. I think it was a special
article. That is a category we have for thing that have documentation but
don't involve the classical kind of research.
DR. GORDON: No, I know that. I
wasn't asking in an accusatory way. I was wondering if that might not be a
way to open up publication to some of these other issues and deal with them in a
thoughtful, critical way.
Phil.
DR. FONTANAROSA: I would just like to
comment on two of the categories of articles you mentioned, one, reviews, and
one, commentaries or opinion pieces. We require a very systematic approach
for reviewing articles, to look at the totality of the evidence.
For example, the executive summary of the
NCP Cholesterol Guidelines that are published in today's issue of JAMA is the
result of a summary and a review of more than 800 references in a 200-page
document vetted by 27 experts over about two years. I think if someone
looked at the evidence behind the CAM therapy with that type of rigor, I think a
journal would make a mistake not to give it very serious consideration.
On the other extreme, our opinion pieces, or
commentaries, I gave you some data for our acceptance rates overall for
JAMA. I will tell you that the acceptance rates for commentaries are even
lower than that.
We get a lot of papers that come in to
stimulate ideas or thought, or to provoke attention. Many of those tend to
be, quite frankly, not well supported by references, but floating ideas, and we
really have to make a determination if we want to spend space on those that
would eliminate space from a research paper.
So I would say that the two extremes are
rigorous totality of the evidence for reviews, absolutely. Commentaries or
opinion/thought pieces have their place, but they tend to fair less well.
DR. CAMPION: I would just add that
opinion pieces are certainly an appropriate forum for discussion of the issues.
Whenever there is some hot area of
controversy in medicine, we tend to hear about from people and get opinion
articles. I am wondering why we are not getting much about alternative
medicine and CAM, and I wonder if it is because CAM is actually a lot less
controversial than some would say. It is there; it is accepted by people
that use it.
Perhaps people have some perspective on
it. Physicians are well aware of its popularity and may not be as
threatened by it as is sometimes said. Perhaps it is not as
controversial. This does not mean it is accepted as effective, but as a
part of our system and of what the consumer wants.
DR. LAINE: Part of our aim in inviting
a series of papers, the papers in the series are much of the type that you
describe. There is a little bit of reviews that are not as critical as we
would like, but most of the papers in that series of papers aim to describe the
context with which alternative medicine exists in the medical community and the
larger society. So, economic issues, ethical issues, medical, legal
issues, that have some relevance to our readership.
So while we are still waiting for the right
for the rigorous scientific evidence about specific therapies, we hope that
those sorts of articles help conventional physicians understand the context that
this whole discipline exists in.
As a sideline, I think there is a
perception, like Dr. Relman said, that the conventional medical journals are
biased against alternative medicine, papers just reporting on alternative
medical therapies. I don't think we are. In fact, one of our hopes
is that this will show that we are interested, and maybe will stimulate people
to send their research to us. Then, of course, it has to go through the
review process.
But one of the reasons we don't publish
much, is we don't get much. The second reason is, of the stuff we get, a
lot of it has methodology problems, but that is no different than a lot of the
original research that we get on conventional therapies.
DR. GORDON: Thank you. My
thought was that there may be some articles that are equivalent to discussions
of the hypothalamic pituitary adrenal access, for example, summarizing the data
that may be interesting, and certainly would be interesting to readers of
mainstream medical journals, as well as, perhaps, opinion pieces.
Dean, and Joe, and Effie, and Wayne.
DR. ORNISH: Well, again, I want to
thank the people for such eloquent testimony. I really appreciate it.
Several people have said that a distinction
should not be made between CAM and other medical modalities, either from the
standpoint of funding or publication. I certainly completely share that
ideal and your commitment to doing good science. It is certainly how I
spend most of my time, but we have heard testimony from several people who have
testified before our Commission that certain journals are more likely to publish
an article showing a negative finding from a CAM modality than a positive one.
I am addressing this question to Dr.
Campion. In the three priorities that you outlined in your testimony a few
minutes ago, the top one was to give priority to those few complementary and
alternative medicine methods that can cause harm.
Do you also have the same commitment to
articles that show safety, efficacy, and effectiveness?
DR. CAMPION: I think, as Dr. Roman
outlined, the basic principle is, we will consider any manuscript on it
merits. If the subject is important, if the intervention is important,
which means it is something that is in wide use or has potential benefits, we
will consider it. We don't get many of those. I am not sure if we
have gotten any.
We do publish a fair number of negative
studies, over 20 percent of the randomized, controlled trials that we publish
are negative studies. Those are of conventional medicine. We think
that negative studies are more important than people realize, both with respect
to CAM and with respect to conventional medicine.
DR. GORDON: Joe.
DR. FINS: Dr. Fontanarosa uses the
phrase "a reputable journal," and as a conventional practitioner, when I see
something in the Annals or JAMA or the New England Journal, I feel much more
comfortable in feeling that it is true, at least by the standards that I have
lived and practiced by.
Dr. Relman, this question is directed to
you, but to any of the editors, I know there is a consortium of medical editors
that have a working group that have published standards.
Is there any outreach to the CAM journals,
or at these other medical journals? What are the criteria, and how do we
know what is a reputable journal? Because I think that is really the
threshold thing.
Yesterday or the day before, we were talking
about reimbursement for benefits if things were in a peer-reviewed journal, but
the question is, what is a peer-reviewed journal; what is a reputable journal.
How do we establish what the threshold is,
and does that organization, that entity of journal editors, have a role in
establishing what the cut-off might be?
DR. RELMAN: Although I was one of the
founders of the Vancouver Group, more years ago than I can quite remember, and
as of the time I stepped down 10 years ago, there was no attempt to define what
was a good journal or what was a bad journal. The membership in that group
was fairly arbitrary, and it didn't have much to do with quality. It had
to do with other relevant editorial things.
So I would ask my colleagues who are now
active members of the Vancouver Group whether there is any attempt to define
quality, but I would also say that I would be very dubious about any such
attempt. It has got to be very arbitrary. At the very least, you
have to say it ought to be peer-reviewed if it is going to publish original
research.
If it says, no, that is not what we are
about; we are going to publish commentary, then you don't need, necessarily,
peer review, but if you are going to publish original research, it has to be
peer-reviewed. So that would be my only observation.
DR. LAINE: I have more recent
experience than Dr. Relman's with the Vancouver Group, because it met Thursday
and Friday of last week in Philadelphia. So I spent two days with the
Vancouver Group. That isn't its role. It is a volunteer group of
editors from medical journals who came together to create a document called the
Uniform Requirements for Manuscripts Submitted to Biomedical Journals to create
some standard guidelines that journals can, or choose not to, buy into.
I think, from speaking with people who have
been on the Vancouver Group since it started, it sounds like originally it was
more focused on the format of the references, and the nuts and bolts of putting
together a manuscript.
In its current inclination, in the revision
of that document that is in progress, a lot of concern with ethical issues that
relate to publication in biomedical journals, but not to give editors some place
to refer to when they are trying to sort out difficult issues related to
conflicts of interest on the parts of authors, reviewers, and the like, but not
in any way setting criteria for what is a good journal and what is a bad
journal.
DR. FINS: It is not unrelated because
the other issue is the firewall issue, and advertisements and supplements in
some of the CAM journals.
DR. LAINE: Right.
DR. FINS: So there may be a role for
the Vancouver Group. For CAM journals, if they were to accept membership
in this consortium, it might lift the standards of the ethical issues, the
homogeneity of references, and there may be some cross-over effect.
It is just an issue that might be worth --
DR. LAINE: Right. That is an
interesting point, because one of the things in this document are
recommendations about advertising and where it should sit, and where it
shouldn't sit, and what types of products are appropriate according to this
volunteer group of editors to be in biomedical journals. That is an
interesting point.
MS. WOOTTON: If I could just make the
point that the blue journal, the Journal of Alternative and Complementary
Medicine, does not accept advertisements at all. This was a conscious
policy right at the very beginning at its inception because it is such a tricky
area for advertisements. So we are clean.
DR. RELMAN: Let me interject. I
think that is just great. If I had had my way when I first became editor
of the New England Journal, I would have said to the owners of the journal, live
on our modest profits from subscriptions and classified ads. We were
probably the only journal that could have made a profit from just subscriptions
and classified ads, but fortunately, not yours.
MS. WOOTTON: Absolutely.
DR. RELMAN: Most journals are now
caught in the economic vice of advertising income and conflicts of
interest. This is not irrelevant to your concerns. Conflicts of
interest between those who profit from the sale of alternative therapies and
alternative devices, and so on, and those who set policies, set government
policies, and constitute advisory groups, are rampant, and you ought to be
worried about that.
DR. GORDON: Dr. Campion, please.
DR. CAMPION: I would just add in
response to your question about journal quality, there is no stamp, and there
should be none. Journals can change over time, but journals have to be
judged on the process, on what they publish, and on their place in the scholarly
community, how readers, the critical audience responds to them.
One indicator of that is the impact factor,
how often do other researchers and scholars quote articles from any particular
journal. That is just one rough indicator.
DR. GORDON: David.
DR. RILEY: We send all authors the
Uniform Requirements for Manuscript Submissions and the Consort Guidelines in
terms of publications. Now, of course, they don't always follow it, and
lots of times, that is probably the primary reason for rejection of original
research articles.
DR. GORDON: Effie.
DR. CHOW: Thank you very much for your
input. I have got many questions, like Wayne usually has, but I will
restrict them to one or two.
DR. GORDON: If you have too many
questions, we won't have much lunch.
DR. CHOW: Regarding Dr. Campion's
remark that it may be more accepted than we believe it is, coming from an era in
1970-something when acupuncturists were jailed, and homeopaths were jailed, some
of the leaders were jailed, and Christopher Hill from holistic health was
jailed, and we were helping to get them out of jail.
I would say it is more accepted now, but it
is acceptance on the public level. Now it seems like we have the challenge
of influencing or educating the top level echelon of scientists and policymakers
and so forth. In your reviews of the papers -- 9,000 reviewers, that is
really a lot -- you talk about physicians being the managers of CAM processes
and so forth.
How much education do you think is enough to
educate the physicians and the health professionals who know, really, basically,
nothing about energetics or any of the practices?
That is our educational question, too.
This goes into research. So I am curious, and I think we would like to be
enlightened as to, how much education do you think will make a physician and a
nurse, a physical therapist, et cetera, qualified to judge the value of a
particular practice.
DR. RELMAN: May I respond to
that? Education has to follow, not precede, the evidence. You will
not influence what the leaders of American medical education teach and what they
believe without presenting, without having available persuasive scientific
evidence.
That is why it is so important to support
research, to publish good research, to teach those who believe in the value of
alternative medicine how to do good research. That is the only way.
There is no other way that you are going to influence the real leaders of
American medicine, and there is no other way that you should want to do it.
DR. GORDON: Dr. Campion, did you want
to respond?
DR. CHOW: We do believe in
research. I just wanted to say that. That is a big issue here.
DR. CAMPION: I believe that education
of physicians should mainly focus on trying to be better physicians. There
is plenty for physicians to learn already, and there is this huge, poorly
defined area of a million different types of CAM, which everybody knows, there
is not a lot of objective data there.
Hence, I don't see need for trying to inject
the medical curricula with quasi data, or some pretense of data when there isn't
any. I think physicians need to be aware of what their patients want,
where their patients go, what other practices are involved, particularly when
they come in direct competition.
DR. GORDON: Phil.
DR. FONTANAROSA: I would like to
respond briefly, if I may. Your question about how much education is
enough is a very difficult question. Being involved with teaching two
courses to the first-year medical students at Northwestern, I can tell you that
time in the curriculum is rare for adding on any additional materials.
In fact, if you add something, something
else has to get bumped out. There are so many hours and so many ways that
you can do it. So I would agree with Dr. Relman, that decisions to add
things to the curriculum must be based on existing evidence and a good reason
for those being introduced, and bumping out something else.
From the standpoint of how much education
for physicians in practice, a lot of that is self-directed, of course, by
continuing medical education. I do think that physicians need to be aware
of the various CAM therapies, their limitations, their applications, not that
they are going to practice them.
I think it would be just as much a mistake
for a physician who is not trained in acupuncture to perform it as someone not
trained in orthopedic procedures to set a broken wrist -- there needs to be that
expertise -- but to be aware of the current information available on these
therapies is important so that when patients ask their physicians these
questions, they won't just dismiss the question because of their lack of
knowledge, and they will be able, more importantly, to see how the CAM therapies
might interplay with the conventional therapies, drug/drug interactions and so
on.
DR. GORDON: Wayne.
DR. JONAS: Thank you for some very,
very wonderful comments by everyone. That was a good discussion and
panel. I hope I can formulate this. I will put my question
first. How about that?
Do you think anything needs to be done in
this area that, we as a federal body trying to look at federal regulations, need
to do?
I don't personally see anything that needs
to be in this particular area. It looks like the process is going on like
it ought to go on, both with the biases and the lack of evidence. I think
anyone who reads the historical literature and the sociology of science sees
that journal publications is the world in which biases are fought out.
We get data and we have editors and
reviewers that are biased, and then there is, hopefully, an open and full
discussion, and eventually some of the good stuff forms to the top. There
are multiple examples of this. Parapsychology is fraught with them,
chiropractic has documented this recently, Ernst has documented both sides of
this problem in publishing, the marked publication bias in favor of positive
studies in the complementary medicine journals, very marked.
The reverse of that, the reviewer bias
against some complementary therapies among the conventional reviewers. So
I think this exists, and Davidoff [ph], actually, at a previous conference, said
this directly. The question is, is there anything to do about this,
because the bottom line is, there isn't very much good research.
So if the goal for all the journals is to
get high-quality, rigorous research -- and let that be the arbitrator of this --
if that doesn't exist, is there anything that we have in relation to this, other
than what we have already discussed, which is, let's try to get better and more
research infrastructure going, and actually outcomes, so that we have a better
selection among all journals to pick from?
I am wondering if any of you have an opinion
about that. Is there anything that should be done about these issues, from
the publication point of view, anything that we should be doing?
DR. GORDON: Please, respond.
MS. WOOTTON: Can I respond to that
one? I think I would go back to the idea of innovative methodology.
This is what the CAM journals can do best, is to nurture new methodologies that
are rigorous but bring in new ideas, new approaches
To go back to my recommendations, I think
probably the middle one, that there needs to be more research money for
practitioner training schools because they are the ones with the knowledge and
the insights that can bring forward these appropriate methodologies.
At the moment, there is a dearth of training
there. I think Richard Hammerschlag addressed this one extremely
well. That would be my recommendation.
DR. RELMAN: Dr. Jonas, I am on your
side. I preach the same sermon that you are preaching. We need more
good evidence. In the fullness of time, with good evidence and full
publication, the reliable will be sorted out from the unreliable; the true from
the false.
I would take exception to my colleague,
Jackie Wootton's, suggestion that we practitioners ought to be taught how to do
research. That is a special skill. It requires a different kind of
discipline, and neither in so-called conventional medical research, nor in
alternative medicine research, I think, can you expect that the average
practitioner is going to play an important role.
They can be part of a team, but the team has
to be directed and disciplined by people who are professional investigators and
who understand the discipline of clinical research.
MS. WOOTTON: Could I just come back,
quickly, to correct any misapprehension. I am not saying that
practitioners should be taught research methodologies. I am saying that
practitioner training schools should be given encouragement to develop new,
innovative methodologies, because I think this is where the innovation will
come, not by channeling and focusing down the same route that the conventional
biomedical research is going in at the moment, whilst at the same time,
sustaining the rigor and the basic principles of scientific methodology.
DR. GORDON: Thank you.
Other responses to this question? Dr.
Fontanarosa?
DR. FONTANAROSA: Dr. Jonas knows this
all too well, from his previous experiences at OAM. I think that the two
places that there might be a way to improve this is being sure that the grant
review process is such that there is prioritization of important, answerable
research questions. So clear prioritization of grant funding.
The other seems, probably, easier said than
done. There are, I can't remember how many, national independent centers
for CAM research around the country, each sort of focused on its own area of
expertise, and I wonder if some better collaboration among these centers might
help to answer questions more efficiently.
DR. GORDON: I wanted to ask you all,
too, to follow up on Wayne's question, whether there might not be a place for
the editors of some of the journals to give seminars to help some of the
investigators develop more appropriate tools for presenting research and papers,
a kind of outreach, perhaps, at some of the conferences or some kind of
independent meeting.
Would that make sense?
DR. RILEY: I think if people focus on
the Uniform Requirements for Manuscript Submission and the Consort
Guidelines. The Consort Group meets regularly. There are other
guidelines being proposed now, the Moose Guidelines for Outcomes Research.
The information is out there, but it
probably needs to be provided more to CAM investigators, or CAM authors when
they are writing up data for submission.
DR. GORDON: I was thinking of
something more interactive, actually, a kind of encouragement and a kind of
working with on developing papers of higher quality.
DR. LAINE: I think developing the
paper might be too late a step, because once the data are collected, the data
are the data. If the paper has good data and is addressing an important
question, as an editor, you can fix up the presentation. That is a big
part of our job, but you can't fix fundamental study design.
So I think there may be a role for the sort
of activity you are talking about, but it has to be earlier in the process.
DR. RELMAN: Dr. Phillips, in
describing the program at Harvard, was telling you that one of the things they
try to do is train people interested in alternative medicine to learn how to
design good studies to find out whether what they are doing works or not.
That should be part of the education of people who want to make a contribution
to the field.
DR. GORDON: Thank you.
Tieraona.
DR. LOW DOG: It is quick, because
everybody is hungry.
DR. LOW DOG: Thanks for all of your
comments. My question relates to the database and self-described experts,
or what they self-describe their expertise in.
There has been wonderful articles in all of
these journals, but some mistakes continue to be repeated, especially in the
area of botanicals, which I think physicians are interested in because of
potential herb/drug interactions, and because they are pharmacologically active
substances.
So we get articles that are published that
have the wrong species identified. So we say Siberian ginseng is actually
Panix ginseng, which is a completely different genus, or we have an herb/drug
interaction article published that talks about hepatotoxicity of echinecea, but
having some mistakes around the biochemistry.
So I think that those are errors we wouldn't
have in conventional medicine because we are more familiar with the
pharmacology. Have you thought about getting botanists, or trying to
expand the database a little bit more, so that they have specialized areas, just
to make sure that those errors don't occur?
DR. LAINE: Yes. That is
something that we constantly do when we go to our reviewer base. We don't
have any process or the resources to go check into people's credentials.
Once they have done a review for us, each reviewer is graded, and that
information is included in our database. Somebody whose done a lousy
review for us is unlikely to be chosen to do another review, but we have to rely
on what people tell us their area of interest and expertise is.
We do go out and try to find reviewers in
CAM therapies, and in other areas, too, where there seems to be a paucity of
expertise among our reviewer database, but mistakes will always get by. I
think it is probably just as common in conventional medicine, although in areas
where there are lots of reviewers with that background and expertise, it is
probably less likely.
Particularly, in alternative therapy, it
sometimes seems like we are hitting on the same reviewers over and over again,
and then the potential is there for their biases to creep into the reviews,
which is another problem, different, but maybe just as great as inaccurate
information.
DR. FONTANAROSA: I would agree with
Dr. Laine for the most part, and I would add one thing, that in addition to
appropriate reviewers for papers, and this is true of any paper, if there a new
mutational analysis for a genetic predisposition, you try to get someone
familiar with that methodology, the same thing.
I would also add that editors have a
responsibility in reviewing papers, not solely to rely on the reviewers
comments, but to do independent work on his or her own, to pool research
articles, to try to verify, independently, names of drugs through various
textbooks or other resources to find that out.
Once something is published, it is really
out there. There is no pulling it back easily. So to try to be sure
that these T's are crossed, I's are dotted, the right drug is named -- or, the
right herb is named, excuse me -- is very important, and I think it is also the
editor's responsibility, in addition to the reviewer's information.
DR. GORDON: Thank you. Thank you
all very much. This has been a wonderful panel, and we have really enjoyed
the discussion and look forward to continuing to work with you all.
We are going to take a break now for
lunch. We will come back at 1:45 for small group meetings. Small
groups will meet until 2:45, and then at 2:50 we will come back here for the
large group.
[Lunch recess taken at 12:50 p.m.]
+ + +
A F T E R N
O O N S E S S I O N
[2:55 p.m.]
DR. GORDON: Which group is going to
present first? Tieraona. Group IIIA:
CAM Research and Publication
DR. LOW DOG: My panel, we had Tom, and
we had Joe, and we had Julia, we had Conchita, we had George.
So our first question was, evaluating the
research literature. So we tried to look at barriers and obstacles that
were involved, and we divided it up into two groups, one was evaluation of
research literature by practitioners; how could they use it to change their
practice habits, and then we also divided it up into reviewers, people that were
actually reviewing the literature.
For the practitioners, we feel that
everybody would benefit, conventional medical doctors, massage therapists,
acupuncturists, chiropractors, if all practitioners had training in school, or
through continuing education from people who are already graduated, in how to
critically evaluate published research.
That would include conventional
practitioners having some familiarity with unique aspects of evaluation of
CAM. It would also allow CAM practitioners to have a better handle on how
to critically evaluate the research that they read in other journals. So
we had that.
Also, for practitioners, sort of in that
area, we wanted to encourage the continued development and support for training
CAM professionals who can teach research methodology and evaluation, because
part of the problem is, who is going to teach in these schools. If we are
saying we want the chiropractors or the naturopaths or the acupuncturists to be
able to evaluate the research, we have to have people that are capable of
teaching them in their schools.
To that end, we encouraged collaboration
between the conventional academic institutions and the CAM schools. So
there is a wealth of people who are well-trained in research methodology at
universities to be able to help teach in these schools.
Also, we wanted to encourage funds that
could help support and sustain library types of materials. A lot of times,
large academic institutions have endowments and funds that are not available to
CAM schools, and that there should be some sort of funding available or set
aside so that they could have access to journals, MEDLINE, computers, et cetera.
DR. GORDON: Question. In this
first one of training people to evaluate research, did you have any particular
pathway by which you thought that could be done?
DR. LOW DOG: Well, part of it is
already being done through NCCAM, who is helping to teach CAM practitioners
research methodology, but we also feel that part of this is going to have to be
done in the short term through collaboration with universities and academic
centers where you will have Western-trained people, basically, going to CAM
schools to teach research methodology.
The ideal, actually, would be to have people
that are specialists in their own modality go through and learn research
evaluation. We are hoping that they could use that through NCCAM, such as
what we heard today, through NCCAM means.
I hope I answered your question.
DR. GORDON: Sort of like NCCAM having
a training program.
DR. LOW DOG: With the sole purpose not
to train researchers, but to train people who teach practitioners how to
evaluate research. So a little bit different there.
Then again, we wanted to make sure that we
earmarked funds to accomplish, making sure that practitioners could have access
to this.
Then we separated evaluating research
literature, looking at barriers and obstacles, into reviewers, people that just
review the evaluation of this literature separate from publication. We
have carved out this niche.
We just, again, wanted to encourage that
there be at least somebody who is reviewing it on the team that has familiarity
with that CAM-specific modality, so that they would know if that was even
appropriate; was it appropriate to test this herb for that purpose so that there
is somebody specific.
DR. GORDON: I'm sort of lost.
What is the context in which you are talking?
DR. LOW DOG: When you are evaluating
research literature, like for doing a systematic review, when you are doing a
meta-analysis, when you are gathering data, that those types of reviewers need
to also have some sort of expertise, or have some sort of collaboration with
somebody who knows about CAM.
We didn't have much on there. We just
sort of thought that came before the published issues. That is all we had
for evaluation of research literature.
Was there anything I forgot, guys? No?
So the next question was, publication of
research results. Again, here, we tried to look at ways that we could
promote and improve the availability of research being published in
peer-reviewed journals.
One of the things that we really did want to
encourage, because you can't mandate, but we just wanted to recommend that
peer-reviewed journals involve at least one person on the review team when they
send an article out for review that was specifically familiar, or had expertise
in that CAM modality. They don't have to be experts in the research
methodology. They have other people for that, but just the appropriateness
of the way the study was done involving that modality.
Part of what we tried to consider about
publication was, one, we don't want complementary and alternative medicine to be
seen as second class. We would like us to try to get more of the articles
into peer-reviewed journals, but we thought, perhaps, since we do believe there
is some bias at this point, which may be just because we haven't got to the
place where we have good enough studies, that maybe NCCAM could do something
like, either consider a quarterly journal, less frequently; more frequently, or
do what we call a "year's best," where they take the best studies that have been
done in CAM for that year, or six months, or however frequently it is done, and
publish that and make that available, similar to what ODS does now, so that you
know what the 25 bests were for the year.
We thought that that might be a way of
making people more aware of the research that has been done because maybe they
didn't get into the New England Journal or JAMA.
We also just bandied around other ways of
getting that information out there, and wanting to encourage NCI, CDC, Office of
Dietary Supplements, HCFA, people who are already taking trials and summarizing
or putting them on their sites. We would like them just to consider the
inclusion of CAM trials that were well done, and putting them in their sites,
because sometimes we think there is just an exclusion of them for no real
reason, maybe just a reminding that good trials should be included there, too.
Anything on publication stuff that we had,
that we bandied around?
This took a lot of time. We had a lot
of work on those issues, about where things should be published and who should
pay for what.
Questions 3 and 4, we sort of put
together. This was looking at issues around non-profit support, people
that are not for profit, and private sector support.
Based on some of the previous testimony that
had been given to us, we came up with a couple of ideas that we liked. One
was that there is a lot of private foundation money and not-for-profit money out
there, but nobody knows about them. So, how would a CAM researcher even
know they existed?
We thought that NCCAM might be able to just
have a site under their researcher site, where they just actually list contact
names for foundations, so that if you are an acupuncture wanting to do a trial,
there is a place that you could go to that you could get information of other
foundation that might be willing to sponsor it, and that they could maintain
that as sort of a liaison.
We weren't sure who it would be, this
ambiguous, appropriate government body, but we wanted to have an appropriate
group to serve as a coordinator for a group of public, private, and governmental
agencies who convene to discuss how to better coordinate CAM research. We
think there is a lot of duplication. We think there is a lot of
discoordination, that there is precious little money, and the money is sometimes
not being used in a very coordinated fashion.
So if there was a group that could come
together that could help coordinate the public money, the private money, the
government money, the foundation money, we might be able to get more work done
in a better and more quick fashion than in this disjointed fashion it is
now. We didn't know if that was NCCAM or who, so we just left it
open.
Finally, for foundations and not-for-profit,
we wanted to recommend that we try to get a group of them to pool monies
together, so that they put a CAM pot together, if you will.
Some of them, we heard, they are only
willing to put so many dollars in; so that we get them to contribute a group of
dollars, and then they could announce a competition, and then could take
applications in and get the best few that could compete for these CAM research
dollars. We might be able to get some bigger studies funded, instead of
$10,000 here and $42,000 there. If we could get some of them to come
together and pool their research money.
We didn't address Question 5.
DR. GORDON: Either additions from
Tieraona's group, other points that anyone in the group wants to make, or
questions for her about this? Wayne, go ahead.
DR. JONAS: What was Question 5?
DR. LOW DOG: It was CAM research and
regulatory process.
DR. GORDON: Other questions for
Tieraona? Because I have one, and I don't know whether this fell into
Wayne's group or yours, or somewhere in between.
Oh, you wanted to ask a question?
DR. JONAS: Yes. I just wanted to
make a comment and add something that has worked in the past and could work in
the future, and that is OMAR. They are the ones that do consensus
conferences. When we were originally looking at the whole list, gee, what
ought we do through OMAR.
A lot came up. We did the mind-body
stuff, we did the acupuncture area, but there were a whole bunch of herbal
products in which the question was, gee, is there enough research to currently
recommend under what conditions that these are safe and effective.
It is exactly in those controversial areas
that consensus conferences are held, to have the debate and the discussion, and
also bring out the current evidence. So they, I think, would be an area of
focus in terms of some of the areas.
DR. GORDON: I want to ask Tieraona,
both you and Wayne, the question, yesterday when AHRQ and Brian were talking
about different ways of producing information. Was it your task to figure
out how all that should go together? Was it your group rather than
yours? It was not, okay.
DR. LOW DOG: I am sure it was
Wayne's. I know it was Wayne's.
DR. GORDON: I don't think we can
necessarily do it here, but I would like to hear some more thoughts, like the
consensus conferences, which I think is really important, about an overall
strategy, because I think what we want to do is make some recommendations,
should we go in some of the direction of outsourcing, in a sense, to private
groups, like the Cochrane Collaboration. The production of information,
should it go to AHRQ, should it be NLM, or NCCAM. I would like to hear a
little discussion here about that.
DR. JONAS: There is a real debate
within NIH as to whether they should do that. They have done it in the
past, and there is a real debate as to whether they should continue to do it.
For example, they contract with groups to do
special databases to produce research on health services research and cancer,
and a variety of other things, toxicology.
Some of the areas they are not particularly
happy with having to do that, but on the other hand, they do it a lot. One
of the things that might be useful would be to actually contract with a group
that does an ongoing summary of current information, past information. I
think that would be a very useful thing, and it wouldn't be very
expensive. We actually looked at the cost of that, and it is not very
expensive.
DR. GORDON: Yes. I would like to
hear other people's thoughts about that, because I think this is a really
important issue. I think this may be one of the ones we want to address in
the Interim Report. It may be complex, but it is reasonably
straightforward at the same time.
DR. JONAS: One of the issues is that,
often, people will look at those sites and say, that is the authoritative site,
and therefore the individuals that want to market a supplement, if it is listed
on that site, then they will say, okay, now we have an authoritative body that
has said this is worthwhile, we can market it, and they will use that through
the courts and things like that. So there are complications to doing that.
Again, the government is nervous, rightfully
so, lest they be interpreted as recommendations in some way.
DR. GORDON: But AHRQ does that, in a
sense.
DR. JONAS: AHRQ no longer does that,
actually.
DR. GORDON: But they do these, what
are they called, evidence reports.
DR. JONAS: Yes. They do do
those, exactly. The Cochrane work does do that. So they do do that,
and they have a whole process for making sure that you don't take this as a
recommendation, that they are available for groups that want to then make
guidelines out of those, if they feel that they warrant them. But it is
possible to do that. That becomes very expensive, however.
DR. GORDON: If AHRQ does it.
DR. JONAS: Yes, because if they are
doing those evidence reports, they are much more elaborate than simply summaries
of current reviews, just with a database, or even systematic reviews, than what
Cochrane is doing.
DR. GORDON: Tom, and Joe.
MR. CHAPPELL: I just wanted to
maintain a principle in the choice, the ultimate choice here, that CAM research
has access to practitioners and to the public.
DR. GORDON: Exactly.
MR. CHAPPELL: So that the more public
the domain, the entity that is doing the evaluation and the publication, the
better.
Now, if the public entity decides to
privatize but still maintains control, that would be fine, too. I just
feel that we need a public entity assessing the evaluation of these trials and
taking responsibility for publication to various channels of groups.
DR. GORDON: Great.
Joe.
DR. FINS: I very much want to endorse
the "year's best" concept that you folks came up with. I think that is
really a way of bridging the gap between the alternative medicine journals and
the New England Journal level, and it gives it a kind of validity, and I think
that would be very helpful.
The other thing, the practice guidelines, or
recommendations for reaching out with the clinicians out there, is through the
specialties societies, through the American College of whatever. They
often have board review, documents, or annual updates. If there could be
some kind of linkage with what NCCAM, or whomever is going to do that, with
those entities in reaching out so it gets distributed widely, that would also be
very helpful.
DR. GORDON: Okay, great.
Other thoughts?
Tieraona, go ahead, and then George.
DR. LOW DOG: In the AHRQ, they have
the really big, thick technology report, and then they have that brief summary,
but it is still not consumer-friendly. It would be nice if somehow there
would be some funding. That information is public and it is from the
government, and it would be nice if there was a lay version of that for the
consumer that was just one page, or on a website that would be available as
well.
DR. GORDON: I think it is up to us to
fashion exactly the kind of information we want to have out there about the
research. So these points are going to help us make that recommendation.
George.
DR. BERNIER: We had tremendous
exposure today, I think, to the leadership of medical journalism. I would
like to point out, and this sort of came up in our conference today, that very
people publish what they are interested in in the New England Journal of
Medicine. It is really hard to get into, and you say, if I get one of
those every 10 years, I have got it made.
So it is not a bad sign to take something
less than the Annals and the New England Journal, but I think we have been
believing it is.
DR. GORDON: You mean it is not eternal
damnation if you are not published there.
[Laughter.]
DR. BERNIER: That's right.
DR. GORDON: Okay, thank you.
Other comments? Joe.
DR. PIZZORNO: I appreciate that
comment, George, and it gets back to the question I asked Brian, and that is,
where is the bar. One of the concerns I have is that, if you look at the
New England Journal, et cetera, a very high bar. If you look at the
Cochrane Collaboration, a very high bar. If you look at the AHRQ, a very,
very high bar.
My concern is that, while at some point we
want to reach that bar, there is some standard of evidence that is appropriate
for us to utilize when treating our patients, and I don't think we know where
that bar is. If we could, in our wisdom, come up with some
recommendations, or at least a process, for determining that, I think we could
do a lot of good.
DR. JONAS: May I just comment on that?
DR. GORDON: Yes, please. Go
ahead.
DR. JONAS: One of the things, again,
we just mentioned, is the possibility of a specialized database contracted out
which reports on current research. It simply reports on research.
NLM does this a lot. They are not in the role of evaluating it, they
simply report it, and report it accurately.
DR. GORDON: In a sense, what you are
saying is, you report on it, and you report to height of the bar as you are
reporting on it, you say how good the research is.
DR. JONAS: No. They don't even
report the height of the bar. All they do is just describe it in a clear,
precise way. They do summaries of it, and they produce it and put it in
one place where if someone wants to get that research, they can go there.
It is ongoing, so it is real-time with the current research.
DR. GORDON: Joe, go ahead.
DR. PIZZORNO: Something that we have
done, and a project that we are working on, is, we actually developed, by
looking at what the Cochrane Group did, a ranking system for the quality of the
research.
I am wondering, maybe if we had some kind of
central repository which looked at the research that was out there, and
basically each study was ranked, just how good is that study, how reliable is
that study, that way, we could at least get a sense for where the body of
research is shifting or establishing itself.
DR. GORDON: I think what we have been
hearing is that people need some estimate of the quality of the research.
The researchers need it to some degree, but certainly the public does need that.
DR. JONAS: The way most conventional
journals do this, like Annals has JPC Journal Club in which they report
abstracts of ongoing research. Most of the time, they have commentaries,
because having a score, tagging a score, is very unreliable, and there is no
standard score that everybody accepts. There are fatal flaws of even
high-quality studies, and good studies that are low quality, and so they have a
description of that. Then that gets into a little more complicated --
DR. GORDON: Joe.
DR. FINS: There is a lesson from the
death-and-dying movement, which had a textbook project that Steve McPhee [ph]
from UCSF headed up. It looked at the death-and-dying care content of the
leading textbooks. It has also been done for nursing as well.
Maybe we can reach out to the kinds of
places where conventional practitioners go for authoritative information and try
to get some infiltration of the kind of basic themes that we talked about in the
December meeting, about what the conventional doc needs to know.
I think if it is there, it gives a
tremendous legitimacy. Of course, it would be a conservative part of the
entire spectrum of CAM, but it would be an initial foothold.
DR. GORDON: Tom.
MR. CHAPPELL: Dr. Heirich, in his
first proposal, says, "Congress should instruct public agencies, that is NIH and
AHRQ, to gather data, both on clinical effectiveness of various CAM approaches
and on the relative costs of more conventional allopathic, and of CAM treatments
for the same condition.
"This information, supplemented by other
information found in peer-reviewed journals, should be brought together and made
available in an easily accessible website, which is updated constantly as new
data becomes available.
"The public agency responsible for the
website should be instructed to draw this information to the attention of
insurance companies, managed care organizations, HCFA, and the continuing
medical educational programs and schools on an ongoing basis."
So I just refer you to that as more
specific.
DR. GORDON: Right. We are
looking at several different kinds of data. We are looking at research
data, we are looking at practice data, we are looking at cost data. It
sounds like many people would like that information made available.
Wayne.
DR. JONAS: There are plenty of
examples of how this is done; HIV-AIDS clearinghouses.
Steve, you put together a Rare Diseases
Clearinghouse, the Health Services Research Database. There are many
examples that could probably very easily be modified.
DR. GORDON: Thank you, Wayne, for
that.
Maybe one of the things on this issue, in
particular, is that staff could put together some possible, specific
recommendations for ways to fulfill this general mandate to produce information
for the public and researchers. Then we can pull that together and take a
look at it, and come up with recommendations based on that data, and make that
data available for everybody. Then we can talk more about it.
It sounds like we are all pretty much in the
same ballpark, feeling the importance of this, the importance of some kind of
discussion, if not necessarily a numerical evaluation, the importance of not
only making it available to researchers, but making it easily available to the
public.
Joe.
DR. FINS: One other thing. I
don't know if there are any editors from the CAM journals here, but if there
could be sections in the journals specifically addressing methodology and the
design of studies in the literature tutorial, deconstructing good studies,
explaining what were the elements, as a way of doing a kind of continuing
educational effort, I think the readership would probably benefit from that.
DR. GORDON: That is a separate item.
DR. FINS: A separate issue.
DR. GORDON: A separate item, but on
the same general topic of information about research. Thank you.
Any other issue related to these topics,
related to journals or philanthropy, that anyone would like to bring up at this
point? Yes, Tieraona.
DR. LOW DOG: Just the whole issue of
the public. We certainly didn't adequately address it, and I am not sure
it has been, really, adequately addressed overall, is, how do you synthesize the
research to the public that is truthful. When you take a study and it says
something, what does it really mean, and synthesizing it, because it has to be
more than just this study was done and it showed this, because they can't
interpret it.
So I do like the AHRQ, and trying to come up
with some body that can give truthful information about the research in a lay
sort of way. We really focused more on practitioners, reviewers, and
sites, and things like that, but I think that that is one of the biggest jobs
that we have, is, how do we get the information to the consumer.
DR. GORDON: I think, if the staff can
bring up some of those models to us, we will see the different ways that it has
been done. One of the things I think that has been clear throughout is
that there has not been enough information for the public. It is not
easily available, and it is not answering most of the questions that they have.
DR. LOW DOG: It is often tied to a
product, too, which makes it hard for them.
DR. GORDON: Right, exactly.
Anything else on this? Great.
Wayne, do you want to talk about your group?
Group IIIB: CAM Research Methods, Training, and Concerns
DR. JONAS: We were tasked with
methods, training, concerns, federal agencies, academic health centers, and
design. I made a mistake when I read these, and I thought it was methods
and framing. So I started with that.
So we had some assumptions that we thought
should frame the whole research discussion that we have heard a number of
times. There is a close consensus among some of these. They are
fairly simple. Research is important, we should be doing research; it is
key, it is important. The research has to be high-quality, it has to be
good, and it should include multiple methods. There isn't, simply, a
mono-method approach to understanding complementary and alternative medicine, or
any medicine, for that matter. There has to be multiple methods.
Now, given the fact that there are multiple
methods, we felt like, or, at least we outlined, six major areas that we heard
discussed both in the prior research discussions that were in the summary your
book, as well as over the last few days where people wanted to see emphasis on
certain kinds of domains, if you will, and other domains.
That included systematic reviews; consensus
conferences; meta-analyses; summaries of current research; randomized,
controlled trials; basic science research. We heard that. We heard a
lot of emphasis then on health services research, especially looking at costs.
Cost effectiveness was something that was
emphasized this time; outcomes research and observational data; and then one
that was only mentioned briefly, but I put it in there because I thought it is
very important for public input, and that is qualitative research, to really get
at some of more subtle items that are difficult to capture in complementary
medicine, or address issues that the public finds important that, maybe, is not
captured in some of these other methods. So qualitative research is an
important area, also. We just wanted to frame that.
One of the things that we did not address is
the whole prioritization process, how do you decide how much you put into health
services research and what areas, and should we all do randomized, controlled
trials, or how much basic science research and that type of thing.
So this perhaps, then, is an item which is
addressing prioritization. Perhaps, one of the things that needs to be
done is to have a prioritization process developed, if you will, that is
explicit and clear, and that includes all the major audiences that are involved
in complementary medicine to make sure the kind of data that they need is
produced in research.
So that was the framing idea, and actually,
this is the kind of thing that the Institute of Medicine does. They have
actually already written a number of reports on this, including one we heard
from in the first conference, which said that the public should be especially
more involved in this prioritization process.
For complementary and alternative medicine,
we all felt that that was a very important area, because this is a
publicly-driven phenomena. So, how to do that is a question.
In terms of other mechanisms, we thought it
was extremely important that research be done in multi-disciplinary teams.
That includes not only scientific teams, experts in a variety of sciences in
these areas, but experts in the actual methods, the complementary and
alternative medicine practitioners who actually do this and are trained in this,
as well as public participation.
I think that most people have agreed that
there needs to be good research methodologists, experts in the clinical area
that is being examined, in the complementary medicine area that needs to be
examined, but how to get the public really involved on the research team is a
key issue, and again, probably you need a special item for complementary and
alternative medicine.
We had a discussion of outcome measures,
selecting outcome measures as being important in complementary and alternative
medicine. Several of them that were mentioned that appear to be important
in this area are: quality of life; patient satisfaction; adverse effects; and
then a category that we struggled a little bit with coming up with the
terminology, but special outcomes specific to complementary and alternative
medicine, such as energy or qi, for example; measurements, or the more subtle
aspects that are difficult to capture and may not have a Western conception,
even, and therefore not a Western outcome measure; and then also, ways to
capture unexpected or serendipitous outcomes that occur from interventions that
are focused on healing. A lot of times, things that happen are unexpected.
So again, that is where qualitative research
comes in, to try to capture things that you can't anticipate, don't have a
measurement item for.
We felt that one of the main focuses, in
terms of setting a research agenda that could go fairly quickly into policy, is
the area of safety, that we need to look at safety specifically in the areas of
supplements. We have heard that over and over again, and there are several
ways that that might be done.
Again, many people say that DSHEA somehow
needs to be either fully implemented or modified, or discussion of DSHEA in
order to identify and allow it to get at the safety issues that appear to be
inadequate, currently.
We started to get into different ways to do
that, and then kind of retreated and said, no, we don't want to get into
modifying DSHEA; it is too complicated, but we want to acknowledge that it is
important to do and that this should be done in some way.
Safety also includes the monitoring of
adverse effects, and also the quality of products. There are particular
ways in which that could be done, and we should empower groups like the FDA, the
CDC, the NIEHS, USP and industry, to move into these areas to make sure the
quality is improved and that there is monitoring for adverse effects
interactions in that way.
I suggested but we didn't really discuss,
but we have heard it in the past conference, that the level of evidence, or type
of evidence, should, in some way, be stratified by risk so that those that are
higher risk require more data, more evidence than those that are lower risk.
This is done, actually, in the
government. We heard from the FDA Devices Division, in which they have an
explicit way of doing this. This should be looked at in a broader way,
because certainly some things that are low-risk need different types of evidence
than some things that are high-risk.
Also, in safety issues that needs to be
addressed, is the indirect effects from incompetent practitioners, although that
is slightly different. That is more in the training issue, and
certification and licensing, but it is an important component of safety.
So there should be research looking at safety, and that should be a highlighted
item.
There was a discussion of trying to get at
those things -- again, this was a little bit difficult, and maybe, Joe, you can
help me with this -- getting at the meaning aspects, information about meaning,
culturally relevant information, including anthropologists, social science
involved in providing information about complementary and alternative medicine
research as being very important.
National Endowment for the Humanities, I
think, was suggested as a place that, perhaps, this could be a targeted.
So that was a suggestion.
We then looked at stimulation of support in
research in federal agencies, academic health centers, and foundations, which
was not our charge, but we felt it was very clear that we needed to encourage
funds, stimulate more federal involvement in research. That could be done
through multiple methods, RFAs, Special Emphasis Panels, money.
What else did we say, perhaps opening up
coordinating offices, either in Health and Human Services, initially. Then
maybe in other agencies that are not within Health and Human Services' purview,
perhaps this could be done in a stepwise manner, so you do, first, one in HHS,
and then subsequently, you open up as those areas develop to try to specifically
encourage research in those areas, similar to what happened at the NIH when the
OAM was started and that began to gather a lot of attention, and kind of develop
those areas.
One very touchy area is that, first of all,
I put up there, "should be blank percent of future budget increases should go to
integrative medicine research." I was hoping they would fill in the blank
for me with a number. They didn't do that, they said, well, there ought to
be more, but it should be a significant portion.
There are many ways to do that, but we don't
feel like we should specifically say how much that should be. There are a
variety of methods that could be done, line items, appropriations in language,
requiring reporting on the amount invested every year in these areas in
complementary medicine.
DR. GORDON: Wayne, could you just
define what you mean when you say "integrative medicine"?
DR. JONAS: Integrative medicine
involves the use of complementary and alternative medicine within the
conventional health care system as part of our health care delivery in some
way. It doesn't necessarily mean it needs to be in hospital, it just needs
to be part of the individual's health care complex.
We listed a number of agencies in which that
could occur. Joe just mentioned to me that we didn't address the whole
issue of targeting specific vulnerable populations, areas like end-of-life, but
my feeling is that if we played on the strengths of these agencies, that many of
them have special populations, like HRSA, that they deal with, and that we
perhaps would then get encouragement across the board in terms of different
types of research, especially areas that are outside HHS. DoD, the VA, has
a lot of research capacity and is willing. We heard from them, and they
are willing to do research in these areas.
Let them build on the strengths of what they
do best. Of the six general areas that we framed in the beginning,
different agencies do different aspects of those better than other
agencies. AHRQ, for example, does the reviews better than anyone
else. They do health services better than anyone else. NIH likes to
focus, and does a lot of good work in randomized, controlled trials, basic
science research. That should, perhaps, be an emphasis for them in other
areas, et cetera.
Finally, we also asked, how can there be
stimulation of research in other areas besides the federal government, academic
health centers. I think one of the things we thought was especially
important that we heard over the last couple days was investment in
infrastructure in academic health centers. These academic health centers
include complementary and conventional health centers.
They may require different mechanisms,
different approaches to that, but they all need training, they all need
equipment, they all need expertise in methodology, they all need to take a team
approach, they all need informatics aspects. The federal government has a
number of ways in which they invest specifically in infrastructure to get a
critical mass of researchers, and those should be encouraged.
Under foundations, I think you addressed
this. We didn't talk about it too much, but we agreed, relatively easily,
we could facilitate coordination among foundation, private and federal, through
meetings and things like that, so that they are at least talking to each other,
and talking about the kinds of things they are providing.
In the private sector, there were a number
of mechanisms that policies could be targeted towards. Some kind of market
protection was mentioned for private groups that invest in research and products
and particular practices. I put down patents. That is a major
issue. It hasn't been discussed a whole lot here, but again, that is
another way of coming up with market protection.
DSHEA, we have already mentioned.
Modification or implementation of DSHEA in a way that encourages research,
rather than discourages it; tax incentives, SBIRs. The orphan drug
approach was thought of as being a way of providing some kind of market
protection, or as an example of providing some kind of market protection.
Training. Since I misinterpreted
training as framing, we didn't talk about it. Never mind.
Regional collaboration was felt to be
extremely important. In other words, getting complementary groups and
conventional groups to work, such as in the Northwest, was brought up as an
example of where that is occurring, and should be encouraged.
We didn't really didn't get into details
about how to get state and local governments more involved in the area, but
thought it was important, and having a repository of research methods,
facilities, resources, et cetera, that have an interest and are doing work in
complementary and alternative medicine, an information source for research
itself, not the results of research, which is information, but actually, the
funding sources and approaches, and types of things they are looking for among
these agencies, would be useful.
Oh, yes, we did mention paradigms, and we
assumed that for 20 cents on your tax dollar, you could get a couple.
DR. GORDON: Thank you, Wayne.
Tom, and then Joe.
MR. CHAPPELL: I am wondering if we
could begin a drafting of something for the area of herbs, botanicals, and so
forth, as an interim report to postpone this. We are beginning to get a
better understanding of this, and had a lot of testimony. I think it would
be wise to begin to draft a set of recommendations regarding this whole area of
concern.
Since the committee, this working team, has
identified it as a problem, could we begin to draft some language?
DR. GORDON: So, what is the problem?
MR. CHAPPELL: The DSHEA. So
whether DSHEA is sufficient or insufficient. Do we have sufficient
laws. If not, what are our recommendations going to be?
DR. GORDON: Dean.
DR. ORNISH: This is one of the things
that came up in the discussion we just had, which is whether we get into that
level of detail, or whether we just simply say that we think there are issues
within DSHEA that need to be addressed. I think that if we get too much
into that level of detail, it might be polarizing or distracting from what our
overall mission may be.
DR. GORDON: Did you want to address
DSHEA?
DR. FINS: I think I agree with
Dean. I think the notion is, we have identified problems. Whether it
is resolved with an amendment, a repeal, better implementation, I don't think we
are in a position to address, but I think it is valuable to simply put it out
there that there is a problem, and not to get to the specifics.
DR. GORDON: My thought is, there are
two levels to DSHEA. One is, there are certain things that have come out
consistently in these meetings about DSHEA. One is that there needs to be
good manufacturing practices. Second is, that the labeling needs to
reflect, which is related, what is inside the bottle. The third is, the
FDA has to have more authority, not the same authority that they have, and more
money to enforce the provisions of DSHEA.
So I think there are some basic
recommendations we can make, that we have heard from every part of the spectrum,
about DSHEA as it presently exists, and I think we may or may not want,
depending on an analysis of what is there, to take a look at other
possibilities.
Tieraona.
DR. LOW DOG: I just want to remind us
that the first two things you said are already in place, though they are not
enforced.
DR. GORDON: That's right.
DR. LOW DOG: The first thing is, it
has to be what is in the bottle; it has to be what it says on the label.
That is by law. I know it is poorly enforced.
The second is, GMP, which, the FDA is
eventually going to publish and release those findings. So GMP is
there. It is a matter of giving and empowering the FDA the power to be
able to enforce, or perhaps looking at rather they should have pre-market kind
of authority. The FTC for label claims, the FDA, if it shown to cause
harm, and too, if it is not meeting claims.
DR. GORDON: That is what I was basing
my analysis on. The point is, that I think it is important for us to take
a strong public stand on these provisions that are already in DSHEA. So if
we try it and we really do it, we may find it works rather well, or we may
not. Then there are the whole complex issues that you are talking about of
DSHEA.
Joe, and Tom. Anyone else?
DR. FINS: I would suggest, because I
think there are other issues that we need to talk about here, that maybe we ask
the staff to draft what you just said in the Interim Report that will be
circulated, and then we can deal with the specifics. I think there are
wide areas of consensus, and I think it would be helpful to have a real text in
front of us.
If I could move onto another -- no?
DR. GORDON: Let's finish up with the
DSHEA, and then come back.
DR. JONAS: I agree with what you
said. I want to add one item that relates to this research area, and that
is, it should also be looked at in terms of its ability to facilitate research,
not inhibit research, in addition to those others.
DR. GORDON: Tom.
MR. CHAPPELL: I think we need to add
safety to that list of three that you identified that needs to be looked at in
this Interim Report, and we need to look at the question beyond DSHEA and the
FDA in terms of the efficacy.
I think Dr. Grollman's proposals,
specifically Recommendations 3 and 4 relating to funding efficacy trials at NIH,
are very important here because the problem is, it is very hard to find the
mechanism of action when it deals with this category. It is a far greater
research burden to approach efficacy than it is to approach safety.
So I think safety and efficacy need to be
treated on different levels, different recommendations, and I don't think it is
too complex for us to deal with, so I am glad you are willing to begin the
drafting of it.
DR. GORDON: I think it is complex in
every way, especially politically.
MR. CHAPPELL: Well, that is okay, but
that is why we are here.
DR. GORDON: No, I understand. So
what I am saying is that, for the Interim Report, I think we need to lay out
where we have consensus, and then for the Final Report, if we start looking at
some of the issues, then we can have some time to discuss them and figure out
where we stand.
MR. CHAPPELL: Thank you.
DR. GORDON: Joe.
DR. FINS: I just want to make passing
reference to the idea about the NEH, the National Endowment for the
Humanities. I think one of the things that we really haven't addressed,
that I think we really need to address more fully, is this phenomenon, this
social movement which is CAM and what it means for American society, good, bad,
and indifferent.
I think that the reason I really favor the
NEH is that it is a different kind of scholarship. Conclusions that are
drawn in the medical humanities do not necessarily have to adhere to the
scientific method because they are asking different kinds of questions.
The sociology, our cultural values, why this Commission itself was created at
this time and at this place.
I think future historians will really be
appreciative of the fact that we made a nod to the NEH and the humanities to
address these broader issues, as well. I think a small amount of resources
directed towards the humanities will have enduring effects that will outlive any
of us in this room.
I just want to make an appeal for
that. I know Linnea feels strongly about that, and some of the other
Commissioners. So I hope that that gets some traction.
DR. GORDON: Joe, could you say a
little bit more about what you mean by NEH?
DR. FINS: The National Endowment for
the Humanities.
DR. GORDON: No, I know that, but what
are you thinking of?
DR. FINS: Well, they fund a lot, and
there are state humanities councils that actually go out and foster the fine
arts, literature, history projects, the kinds of things that really address the
cultural richness of our society. I think that the evolution of CAM is
part of our cultural inheritance and the legacy that this generation will leave
to future American generations.
So I think we just need to understand what
it means in a different kind of way. I am a big proponent of the
scientific method for scientific questions, but I think that these are different
kinds of social, cultural, anthropological kinds of concerns.
DR. GORDON: Joe.
DR. PIZZORNO: Jim, I would like to
second what you said about DSHEA. What we have in place needs to be
enforced, and the FDA needs to be funded for it.
However, I also would like to take one step
further, and that is, I believe DSHEA does not have adequate safety components
to it. I think before a product is allowed on the market, there should be
basic safety documentation, and that is not required right now, and I think that
is a serious flaw.
DR. GORDON: Do you think we have
enough consensus to put that in the Interim Report, or do you see that for the
Final Report?
MR. CHAPPELL: You have my consensus.
DR. LOW DOG: Can I say something?
DR. GORDON: Sure.
DR. LOW DOG: There are 2,400
botanicals sold, if you include all the herbs in commerce, 2,400. They
have not all been tested adequately for safety, and that is going to cost an
awful lot of money to test them all. It will limit acupuncturists in their
ability to prescribe and use many of the Chinese remedies because they have many
in them that have very little data that would be accepted or used here.
I agree, DSHEA absolutely missed the boat on
safety, but I think we want to be very, very thoughtful in how we go about
defining our recommendations. If we are going to undertake that, I think
it is one thing to say, we do not believe that DSHEA has adequately addressed
safety.
I think it is quite another thing to try to
say or come up with the recommendations for how they should go and fix that,
because I think it is a huge issue. That's all.
DR. GORDON: Dean, you had your hand
up.
DR. ORNISH: Again, especially in the
Interim Report, we should try to find areas of consensus, and if there are
people who have strong feelings, rather than trying to resolve the differences,
I think we ought to just take note of the differences, see where we can come to
consensus, and then leave it for later to try to resolve them. I think it
is just going to take too long otherwise.
DR. PIZZORNO: Tieraona, I agree with
you on the one hand, because there is a lot traditional medicine we don't want
to lose access to you and I both use.
On the other hand, there are a lot of
products out there that are adulterated. We have had experiences in
Seattle.
DR. LOW DOG: That is GMP.
DR. PIZZORNO: Pardon?
DR. LOW DOG: That is a GMP issue.
DR. TIAN: That is a quality
issue. That is not a safety issue.
DR. PIZZORNO: I concede. In
terms of the expense of safety testing, it is not that expensive. There is
now microbiological testing that can be done that is not particularly
expensive. Any manufacturer who is bringing these products into the market
can spend a few hundred dollars for these real basic screening processes.
DR. GORDON: Joe, I think it is much
more complicated because something may be safe in a biological system, and may
not be safe for humans.
DR. PIZZORNO: We have to start
somewhere.
DR. GORDON: But I think that the issue
here -- I have to say one sentence, Effie, and then you and Ming can speak --
the issue here is that it is very complex, and I just don't feel comfortable at
all getting into it in the Interim Report. Safety is an issue, but how to
--
DR. PIZZORNO: For the Interim Report,
I am okay.
DR. GORDON: Ming.
DR. TIAN: I agree with you, Jim.
I think this is really complicated issue, because whenever we say anything, it
just cannot cover everything. If I understand, most herbs and dietary
supplements are generally considered as safe. Maybe some things are not
safe enough, but when you set up the standard for all the dietary supplements,
there is going to be a problem.
Who is going to do that? That is the
second thing. There is no such standard that we can test all of them,
because we are talking about quality control, GMP. The second one we are
talking about is safety. Number three, efficacy. When this is so
effective to treat any disease, then the dietary supplement is not considered as
a dietary supplement, it should be as an OTC drug.
DR. GORDON: I would like to get off
this topic, because I think it really needs a lot more discussion, and I would
like to get back. We only have about 10, max, 15 minutes more, if that is
okay, Effie. Or, do you have something --
DR. CHOW: I agree with you that I
think we need to be very sensitive about that, particularly when there are other
groups that are dealing with it. I think to make final recommendations
that say we should be communicating with them, or recommend that we communicate
with the other groups, take it very carefully. I don't believe that in
this Interim Report, we should say much.
DR. GORDON: Okay, thank you.
So let's go back and let us focus and see if
there are other issues in this Research Report that we want to deal with.
Anybody else, any thoughts about this?
Well, one thought that comes to mind, in addition to framing, I would like to
talk about training.
[Laughter.]
DR. GORDON: I think we need to make
some recommendations about training. I think some of the things that we
have heard today about training, if everybody is comfortable, we can put
together a kind of synthesis of what we heard from the training panel and what
we heard from the Commissioner's questions, and perhaps even put forward some
recommendations to consider for the Interim Report.
If there is anything anyone wants to add to
it now, that is great. Wayne.
DR. JONAS: Training, in one way, is
part of the infrastructure, development of the infrastructure. I actually
had it up there, I think, if not, I will stick it up there.
DR. GORDON: Yes, it is up.
DR. JONAS: However, the other kind of
unique thing about complementary medicine is that the training needs to be in
order to bridge the standard research methods and individuals that have
knowledge about complementary medicine. It is to address the two cultures,
if you will, as was mentioned in there, or to provide what David Eisenberg calls
dual-skilled individuals, and that should be the focus of the training.
DR. GORDON: Right. Okay, good.
Other research issues that either have been
raised by Wayne and his group, or that you think we need to be addressing?
Some of them we have talked about
before. I just want to bring a couple up, and maybe they will lapse over,
or maybe emphasize the whole issue of integrative medicine, or, if you will,
complex, many-modality approaches. I have a sense that we a consensus on
that, that that is an important area that we want to urge investigation of.
Is that correct? That is, approaches
that not just are just single procedure, but complex approaches that may involve
acupuncture and diet and exercise.
One of the areas, and maybe we want to wait
on this, is the whole area of so-called "frontier science". Maybe that is
one we need to think through more and talk more about, but in terms of making
recommendations for more investigation in this area of energy medicine, areas of
distant healing. I am thinking aloud now.
DR. ORNISH: I guess, Jim, part of
that, if we agree that we should take certain methodological approaches, as
several people testified today, they can be applied to a number of different
things. The only methodological issue becomes, is it measurable or not,
trying to measure qi, for example. How do you do that?
I am not sure where you are going with
that. Are you saying we should devise new methodologies for new
problems? Or, are you saying that we should make sure that a variety of
things be studied in addition to the traditional ones.
DR. GORDON: No. That is a whole
other question, about new methodologies or new instrumentation. No, I
wasn't talking about that. I think, just as with the creation of the OAM,
it focused attention on certain approaches to medicine and healing that were not
being generally considered, so the creation, the recent NCCAM RFA for a center
on frontier medicine began to focus the issue on some of those other approaches
to healing.
It is not that the techniques of evaluating
them are any different, and perhaps we ought to just put this off and let this
go, but whether or not we want to come out strongly on the side of looking at
approaches that are beyond the generally accepted, even though we accept them as
part of CAM, everything from shamanic practice and studying shamanic practice,
to understanding and studying healing at a distance or healing by
intention. That is the thought that was going on.
So it is not a difference in method, it is
just an emphasis on another subject.
Wayne.
DR. JONAS: I think this is very
important to put in, and the reason is because this addresses the paradigm issue
that we didn't talk about. Many, many complementary or traditional medical
systems do not share the same assumptions about fundamental science and reality
that we do in Western medicine. They are literally outside the paradigm of
causality and a variety of other things. Yet, they are an integral part of
their system, the practitioners use them, they frame their therapies based on
them, et cetera, et cetera.
So, how can this get addressed? So I
think to frame it in terms of the fundamental assumptions that currently lie
outside the paradigm; are there ways in which we can use the scientific
microscope to examine these, and is there a way in which the government can
support that.
The other thing that comes into that is that
there is a lot of the public very interested in these areas, and yet the
scientists aren't. So it is another area of public-scientists interest
gap, and I think that justifies it.
There are places where we could encourage
that to happen. I think it is in the basic science areas, through groups
like National Science Foundation, et cetera, using the standard procedures that
they have for trying to develop and encourage good research in those areas.
DR. LOW DOG: I just wanted to say,
that is, again, where you want to collaborate with your medical anthropologists
who have been studying all of this in traditional cultures, looking at how they
diagnose, how they treat, and their whole system of belief, and how that
influences, then bringing your basic scientists and that. But that is
where you want that collaboration.
DR. JONAS: And clarifying, really, in
Western terms what those assumptions are in those societies.
DR. GORDON: The question I have here
-- Effie, go ahead. Do you want to say something?
DR. CHOW: Just a brief thing.
Also, the speaker on psychoneuroimmunology, that is a new science that fits into
this.
DR. GORDON: The question I have here
is a tactical one. It sounds like we all feel this is an important
area. The question is, do we make a recommendation in the Interim Report,
or, do we simply raise this area, and then make recommendations in the Final
Report.
DR. ORNISH: My question is, who reads
the Interim Report? I am still not clear.
DR. GORDON: What, Dean?
DR. ORNISH: Who gets a copy of the
Interim Report? Is it just an internal document, or is it a public
document?
DR. GORDON: The Interim Report is a
public document. How does that affect your thoughts?
DR. ORNISH: Well, I think if it is an
Interim Report, we can include things that we wouldn't necessarily want to see
the light of day just yet. My own belief is that we want to really be
careful on the Interim Report and stick to areas that we have consensus,
particularly at a new administration who is going to be looking at this, and is
going to be looking at how people react to this, even more than looking at it
directly. If it provokes a lot of controversy or polarization, I think it
is going to make it that much more difficult to get our Final Report done.
If, on the other hand, we write something
that we can all stand behind that doesn't cause polarization within the
Committee, which would be the worst thing, then it doesn't provoke a too heated
response from the general public, then I think it is going to make it easier to
continue doing the work.
It goes back to the incremental approach
that we were talking about and that has been presented to us. I think
that, while there is always a tendency that I have to want to do it all right
now, immediately, which is my nature, I am learning a little more in my old age
that there is something to be said for taking a longer view of this. I
think that in this case, that might apply.
DR. FINS: I really endorse that.
I think, up to this current session, we were really very clearly developing a
consensus on 80 percent of the issues. I think we have the potential to
have problems with the membership on issues that are very complicated, like
DSHEA, on specifics about funding. I think we can say that there are
problems out there about regulation of supplements but not get into the specific
details that have the potential to fracture the recommendations.
So I would, again, urge what I urged --
DR. GORDON: Were you feeling that
about this issue, as well?
DR. FINS: Yes, a little bit. I
think there is so much that we have come to agree upon.
DR. ORNISH: Yes. I want to echo
that.
DR. FINS: I would hate to jeopardize
that at this stage.
DR. GORDON: Let me make a
suggestion. Everybody probably wants a little break before Public
Comment. Yes?
So the suggestion would be that this is
clearly an important issue, that it is one that we at least prepare, and I am
looking over at Jim Swyers as I say this, that we at least some material and
some points for discussion, but that we not be planning to come out with a
recommendation in the Interim Report.
I don't think it is just my feeling that it
needs more discussion and needs more solidity to it, and needs more consensus.
DR. ORNISH: Maybe we can have an
internal document, just among ourselves, that lists the more controversial areas
that we want to explore to see how far we get.
I agree with Joe. I have been very
encouraged by how this very disparate panel, who have come from very different
places, is moving much more towards consensus than I ever thought we would see.
DR. GORDON: Does that sound okay, that
we raise the issue? I think that what we can do is, that when it comes
time to formulate it, we can formulate it in a way that will be heard and that
will not create problems; quite the opposite, will gain support.
DR. JONAS: I agree, there are ways it
can be formulated in which it will be heard. I think one of the ways to do
this is to simply acknowledge that there are assumptions that are part of
non-Western cultures that are now part of our culture because there is a
multi-ethnic group of the United States, and that these assumptions need to be
examined, systemologically or in some manner.
DR. GORDON: So I think, as we are
thinking about the Interim Report, we can think about some statements about
where we are, what we recommend, because there is a clear consensus, and then
other issues that are part of our understanding of the field as a whole that we
will be addressing in the Final Report. I would see these other realities
as being one of those issues.
Great. Thank you. Thanks for
lots of work in this condensed period. Let's take a 10-minute break.
We will back at 4:15, and we will begin public testimony at that point.
[Recess.]
Public Comment Session
DR. GORDON: We will begin with James
Sensenig.
DR. SENSENIG: Dr. Gordon and
Commissioners, my name is Jim Sensenig. I am a naturopathic
physician. I was the founder of the American Association of Naturopathic
Physicians, and I have served as the dean of two or our colleges. I am
here today on behalf of the American Association of Naturopathic Physicians and
the American Association of Naturopathic Medical Colleges.
We need medical pluralism in this country
for the same reason that we need diversity amongst the plant species of the rain
forest. It maintains the gene pool, enhances creativity, allows for the
competition of ideas, and stimulates critical thinking.
Furthermore, we do not know which of those
plants in the rain forest or which of the therapeutic systems holds the medicine
that we need to heal our health care system, our nation, and the planet.
It is likely that they all do.
You have been asked by the President of
United States, in my opinion, to not only survey the forest of healing, to
identify the species of therapeutic systems, but also to preserve the diversity
of the ecosystem for the benefit of the health of our nation.
While the details of our recommendations to
the Commission have been previously submitted and are in the written testimony
today, they can be summarized thusly:
First, ask the Congress to commit this
nation to medical pluralism;
Secondly, inasmuch as these diverse systems
constitute a national treasure, use them to pay down the debt of human illness
and suffering in this nation.
Thirdly, nurture the diversity of this
ecosystem by pruning back the barriers to access and by fertilizing the ground
with the richness of our academic, economic, and scientific communities.
Fourthly, we want to thank you all for
having the courage and the energy to put into this project because we know it
will change the face of our health care system. Thank you very much.
DR. GORDON: Thank you very much.
Candace Campbell. Candace has a
statement that she has ready on the Access to Medical Treatment Act. I
have also asked her to speak for two minutes relating to DSHEA, because I
thought she had some information that might be helpful to the
Commissioners. So I think I will let her do that in seriatim, so that we
don't have to just go to it with the Questions and Answers.
So, please, Candace.
MS. CAMPBELL: I am the executive
director of the American Preventive Medical Association, and I came here today
to ask you to recommend passage of the Access to Medical Treatment Act, which
will be introduced this week in the House, and then the Senate soon thereafter.
You have a copy of the bill in the
background materials in the written material I provided.
Why, you may ask, am I requesting passage
during a week when you are talking about research and reimbursement?
Because we because that Americans should have the right to access therapies as
soon as possible, and not have to wait decades for all the research to be in, or
for the FDA to approve a drug. We believe that many lives could be
improved and saved in the interim years.
The Access bill, for those of you who are
unfamiliar with it, would create a federal statutory right for Americans to use
any therapy they desire, so long as they and their authorized practitioner
follow the consumer protection guidelines in the bill.
There are four main categories of things
that would be accessible, drugs approved and used safely in other countries that
are not available here because the companies have not sought FDA approval; drugs
in the FDA approval pipeline that are showing promise, but that are not
available to patients who do not fit the tight clinical trial guidelines;
therapies that are not patentable, and therefore will never go through the FDA
approval process; and therapies that would be called experimental but for which
there is evidence of safety and efficacy.
This last category would include the
unapproved therapy for Lyme disease which cured former Congressman Berkley
Bidell, and about which he testified last year.
APMA and scores of other organizations, and
millions of patients and their practitioners believe that patients should have
the right to make the most personal of all decisions, how to treat and cure
their disease. That choice should not be limited by bureaucratic,
political, or unnecessary financial roadblocks.
Do we really want to criminalize the doctors
and patients who are seeking safe and effective treatments? Do we want to
promote a black market in effective therapies and leave patients prey to
unregulated promoters of miracle cures?
We would rather see Americans going to duly
authorized health care practitioners in this country, instead of having to sneak
across the border to Mexico, Canada, or the Bahamas, to receive treatment in
clinics that may or may not be reputable.
We would rather see data collected and
disseminated about these therapies so that we may all learn and benefit.
We would rather see all Americans have access to the full range of therapies,
not only those who can afford to go to Germany for six months or a year of
treatment, and not only those who are diligent or lucky enough to discover that
they actually have options beyond what the FDA, AMA, state medical boards have
sanctioned.
We would like to see a health care system
that embraces advancements and accepts science from other parts of the
world. NIH should not stand for "not invented here". We believe that
the Access bill provides an appropriate balance between increased freedom and
adequate consumer protections, and we believe that Americans deserve health care
freedom.
When I was sitting in the audience for the
past hour or so, I was biting my tongue during your discussion of DSHEA because,
frankly, I wasn't sure if you had heard any testimony about the Pierson
decision, which we were one of the parties to. That was a First Amendment
case revolving around the FDA's handling of health claims for supplements.
What I suggested to Jim during the break is that you need to be extremely
careful, if you are planning to make recommendations about revisiting DSHEA.
I would suggest to you that the problem is
not so much with DSHEA as with the agency's implementation of DSHEA. Their
cries for more power and money are nothing, if not disingenuous. We won
that case two years ago, after a six-year, very expensive battle.
The appeals court told them that they must
allow health claims, they must define significant scientific agreement, which is
their benchmark for approving a health claim, and which they have yet, two years
after the court case, to define.
In order to force them to comply with the
laws, we filed five health claims after the Pierson decision. They
rejected all five, without having defined significant scientific
agreement. We filed two more suits. We won them both, but not after
more years, more money. I don't think that supplement companies and the
American public should be forced to go to court and spend hundreds of thousands
to force a federal agency to abide by the law.
We have met nothing but lies and
deceit. They cook the books when they judge the science. They cook
the books when they determine how long it takes them to approve a drug
approval. There is an incredible institutional bias against natural
products, and dietary supplements in particular. We have had landmark
victories over the past several years. I am tired of suing the FDA.
I think you have huge problem with the definition of "drug," not with DSHEA.
DR. GORDON: Thank you, Candace.
I wanted her to raise this issue so we could
have some conversation now, but also, just to give a sense of the complexity of
some of the issues as we get into them.
Diane Davis Cole.
MS. COLE: Hi. My name is Diane
Cole, and I am an education coordinator at the University of Virginia in the
Cancer Center. I address you on behalf of health care providers and
educators who are mandated to educate patients and their families at cancer
centers across the country.
What we know is that 50 percent or more of
all cancer patients are using some form complementary or alternative
therapy. We are trying to address the quality of that information for the
protection of the patient. Our patients are very vulnerable to being taken
advantage of by companies and products whose bottom line is profit instead of
cure or quality of life.
Many of them trust their health
professionals to provide excellent medical care, but the want to do more for
themselves that help them feel in control. These patients are making
decisions about, and are spending thousands of dollars on some therapies and
products that have very inconsistent data to support their benefit.
When they search the Web, there is no
standard on which to judge the credibility of the websites. Many patients
will not tell their physicians what CAM therapies they are using, and many
physicians do not feel comfortable advising their patients about what CAM
therapies to use, if any.
Members of our network hear patients express
their frustration and confusion about what they should be doing in terms of CAM
every day. In response to this, we have developed a guide to CAM
resources, which is not exhaustive, but it gives patients a start. This
guide is provided in your packet of information.
Our network offers the following
observations for your consideration based on our experience with this particular
patient population. Students preparing to be health care professional, as
well as those already in the field, should be educated on complementary and
alternative medicine practices and interventions. A better understanding
of CAM services by all health care professionals is the best way to eliminate
barriers and make CAM service more accessible.
An oversight department in Health and Human
Resources must be at the forefront of consumer safety issues, responsible for
the labeling of herbal natural products and supplements. Consumers should
be able to read a label and make good decisions about possible side effects
and/or food/drug interactions.
Medicare and third party reimbursement
should be available to include modalities such massage, acupuncture, and visits
with other certified practitioners. Research in this area could prove that
there is a real potential for tremendous cost savings to the burden of the
present health care delivery system.
Lastly, more research is needed in
complementary and alternative medicine modalities. Research could
encompass case studies and clinical trials that include the study of the placebo
effect.
Thank you for the time dedicated to this
important topic of complementary and alternative medicine that now occupies a
prominent position in the delivery of health care services to or cancer
patients.
DR. GORDON: Thank you, and thanks for
the work you are doing.
Susan Pittman.
MS. PITTMAN: Thank you. My name
is Susan Pittman, and I am a registered dietician, and I am representing the
American Dietetic Association today.
The American Dietetic Association represents
70,000 food and nutrition professionals who serve the public by promoting
nutritional health and well-being. Many ADA members are licensed, registered
dieticians who provide medical nutrition therapy and preventive care nutrition
counseling to hundreds of thousands of Americans each year.
To date, 43 states, the District of Columbia
and Puerto Rico have laws that recognize dietetic professionals. ADA
members base work on sound information drawn from peer-reviewed nutrition
research and credible sources representing scientific consensus.
The members of the ADA generally see
nutrition-related CAM therapies as potential components of medical treatment and
patient care, where sound, safe, and empirically proven therapies can better
serve patient needs.
ADA welcomes additional research that can
support broader application of CAM practices. We believe patients who
utilize nutrition-related CAM modalities should receive care from those who have
appropriate knowledge, training, and expertise. We also believe the
dietetic professionals are valuable members of the extended team providers, and
play an important role in the integration of nutrition and other modalities of
treatment.
Science supports the role of preventive
nutrition and the role of medical nutrition therapy, or MNT, in managing
disease. However, continued research is needed to evaluate fully many CAM
practices, and to provide the substances for evidence-based medicine. ADA
urges that any preventive or treatment strategy, conventional or CAM, be
supported by sound science and evidence-based practice before it being
integrated into a health care strategy.
ADA recognizes that nutrition intervention,
such as MNT or the use of dietary supplements may reduce or eliminate the need
for more costly medications or treatments. In the case of medical
nutrition therapy, we have science to verify the role dietetics plays in medical
care and outcomes research to demonstrate the effectiveness of MNT in treating
diabetes, renal disease, and cardiovascular conditions.
To help consumers make wise choices about
food and dietary supplements, dieticians can provide nutrition counseling and
education, and can work with patients in developing a sound strategy to obtain
nutritional health. Dieticians are the best source for consumers who need
or desire nutrition guidance, and are most qualified to provide advice about
whether to consume dietary supplements, which ones, and in what amounts.
For example, European studies support the
use of St. John's wort for mild depression, which can be purchased for half the
cost of selective serotonin re-uptake inhibitor. While this herb may be
safe and efficacious for some, St. John's wort has shown to interfere with the
efficacy of certain drugs, such as Coumadin, cyclosporine, digoxin, and protease
inhibitors, and should not be consumed by patients who rely on these
medications.
There are many examples of food drug and
supplement drug interactions, which make evident the need for dieticians,
especially as more Americans consider the use of dietary supplements.
ADA believes all Americans should have
access to nutrition services. Such services are covered through
reimbursement payments in some hospitals, home health, and post-acute care
settings, but inconsistently among insurance plans, and generally at levels
inadequately to meet the needs of many Americans, particularly older Americans.
We hope work will progress rapidly to
advance our understanding of the role of nutrition in preventing or delaying the
onset of many chronic diseases, and to substantiate through evidence-based
practice that coverage of nutrition services is a wise investment in public and
private health care programs. Thank you.
DR. GORDON: Thank you.
Audrey Di Maria.
MS. Di MARIA: Good afternoon. My
name is Audrey Di Maria, and I am secretary of the Art Therapy Credentials
Board, which oversees the credentials of about 3,500 art therapists nationally.
I understand that Linda Gant, past president
of the American Art Therapy Association, has submitted material regarding art
therapy research. So I am speaking about art therapy training and
credentialing.
The American Art Therapy Association, or
ATA, regards the masters degree as entry level to the profession. It sets
standards for the training of art therapists that include the completion of 45
credit hours of course work and 700 hours of supervised practical work.
Many programs require more. At the
George Washington University Art Therapy program where I teach, students must
have a minimum of 1,100 hours of clinical work, one year with children, and one
year with adults.
Settings range from traditional psychiatric
hospitals to hospices, prisons, shelters, nursing homes, hospital waiting rooms,
and even corporate board rooms.
Of the 40 training programs nationwide, 28
have thus far obtained ATA approval. Graduates of approved programs must
accrue 1,000 hours of direct client contact before applying for registration
with the Art Therapy Credentials Board, the ATCB. Graduates of
non-approved programs must accrue 2,000 hours. At least half of the 100
hours of supervision required must have been provided by a registered art
therapist, an ATR.
At present, 2,200 art therapists are
registered with the Art Therapy Credentials Board, and thus, are eligible to sit
for the National Certification Examination.
I would just like to say that the music
therapists were very helpful to the art therapists when we were developing our
exam. Individuals who pass the exam, are entitled to add B.C. after the
A.T.R., becoming art therapist, registered, board certified. Currently,
1,200 art therapists have been certified by the Art Therapy Credentials
Board. A recertification program ensures that board certified art
therapists earn at least 100 hours of continuing education every five years.
In two states, Kentucky and New Mexico, the
state licensing boards use the ATCB certification exam to license art
therapists. In 11 other states, counseling bodies give art therapists
seeking licensure as counselors credit for the art therapy courses they have
taken. In two of those states, the ATCB certification exam is accepted in
lieu of the counseling exam.
Art therapists continue to work for
licensure in the other states, as well as in the District of Columbia.
Thank you.
DR. GORDON: Thank you.
Judy Simpson.
MS. SIMPSON: My name is Judy Simpson,
and I am the government relations associate for the American Music Therapy
Association. I would like to thank the Commission for this opportunity to
address research needs and reimbursement challenges for our field.
Music therapy is an established health
profession in which music is used to address physical, emotional, cognitive, and
social needs of individuals of all ages. We have a 50-year history of
contributing to the treatment of individuals with a variety of disabilities and
illnesses, with more recent expansion of services to include prevention and
wellness programs.
Board certified music therapists use both
instrumental and vocal music strategies to facilitate changes that are
non-musical in nature. After assessment of the strengths and needs of each
client, qualified music therapists provide indicated treatment and participate
as members of the interdisciplinary team to support a vast continuum of
outcomes.
To advance the awareness of music therapy, I
have provided materials for the Commission's review, including a CD ROM
containing 35 years of published, peer-reviewed research. This existing
research not only addresses direct benefits dealing with specific illnesses, but
also demonstrates how music therapy can contribute to the amelioration of pain
and distress that sometimes occurs with conventional treatments and invasive
procedures. For example, the clinical application of music during
chemotherapy treatments has been shown to reduce anxiety and nausea in oncology
patients.
Intervention benefits have received
attention outside of our association publications as well. In a recent
Journal of the American Medical Association, music therapy research in a
neonatal intensive care unit was featured. Data on the physiological
benefits of music therapy included improved oxygen saturation levels, increased
weight gain, and shortened length of stay.
These positive outcomes, however, have not
translated into more research opportunities or more access to services. If
we know it can make a difference, what steps are necessary to provide and
reimburse music therapy in every neonatal ICU. How do we progress from any
positive research finding to increased access and coverage for effective music
therapy interventions.
The truth of the matter is that music
therapy is not just a nice thing to provide to patients, but it is a serious
intervention supported by scientific evidence. Even with our long history,
we don't have the necessary volume of research projects to make primary
reimbursement easy. We have nowhere near what other related disciplines
have when it comes to research funding.
The lack of understanding and acceptance by
the federal government, along with limited funding for research, direct
services, and reimbursement seriously restricts access to music therapy
services. Without federal recognition and support, it is difficult to
conduct the multi-site, large sample, longitudinal studies that we need to
demonstrate the outcomes and cost effectiveness third party payers require.
The current method leaves music therapists
as freelance advocates with each provider an insurance case manager to prove
music therapy is a valid treatment worthy of reimbursement.
We know music therapy can make a difference
in health care, but we need help in getting that message to
decision-makers. The American Music Therapy Association would appreciate
the Commission's assistance in securing research funding and third party
reimbursement for music therapy. Thank you.
Panel Discussion
DR. GORDON: Thank you very much.
Thank you all.
Question from the Commissioners. Joe.
DR. PIZZORNO: Dr. Sensenig, thank you
for the eloquent statement about medical pluralism. I suspect you speak
for many CAM providers who feel we have so much to offer, and yet are being seen
as simply a source of cherry-picking a few therapies.
Going along with the idea of nurturing
medical pluralism, what recommendations would you to this Commission about how
to do that?
DR. SENSENIG: Well, specifically, as
relates to naturopathic medicine, we would like to see the encouragement or a
statement, or a position, encouraging the states to license naturopathic
physicians and other CAM providers, as is appropriate.
This issue of credentialing and licensing,
or certification as a prerequisite to reimbursement was discussed in detail by
the Commission, I think, yesterday. We have an interesting situation in
Connecticut that I would share with you. In our state it is mandated that
any plan that covers the services of a medical doctor or an osteopath, also
cover the services of a naturopathic physician.
So that is true for all the insurance plans
in the state, except for those folks who are federal employees or who are
receiving Medicare, because those benefits don't accrue to those patients at the
federal level.
The other thing that we would like to see
as a result of discussions here would be parity for, in this case, all schools
of physicians at the federal level. We are not asking, necessarily, for
any special treatment, but rather for parity with other schools of
physicians. Again, we may be a minority school, but we are still a
recognized school.
I was discussing this with some people at
lunch today, and we were wondering how much our federal government transfers to
conventional, and not to other schools of medicine, including osteopathy and
naturopathy.
Does that answer your question, Joe?
DR. GORDON: Other questions?
Don.
DR. WARREN: Ms. Cole, you were
talking about that CAM preys on the vulnerability of susceptible patients.
Don't you feel that maybe the apparent feeling of being railroaded into
conventional therapies where there is no hope of cure is also preying on the
vulnerable?
MS. COLE: I think, to a certain
degree, it probably is. What I see, sometimes, with the elderly, in being
preyed upon by people who are trying to make money -- and certainly it happens
in all areas of our lives -- what I am referring to there when I am talking
about it, is that when we look at cancer patients and the state of mind that
they are in when they are diagnosed with cancer, they are desperate to find a
cure. Many times, when we are diagnosed, we still think death; we don't
think cure.
We want to try anything that might
help. When we see something on the Web, or anywhere, that has a testimony
of a cure, then someone is going to try that, many times. That is what I
am thinking when I say that lots of times, when people advertise, they are
thinking about the cancer patient, really, as much as they are any other person
who has a serious illness in their being desperate to find something.
DR. GORDON: Other questions?
DR. WARREN: Isn't one of the main
things that happens is that it dashes all hope for people? Once you dash
hope, then they are more susceptible to going into surgery. I feel that a
lot of these people have lost hope in being able to be cured at all.
I don't think that being preyed has
anything to do with it. I believe that people that give people some hope,
maybe not a cure, but just some hope of maybe a better quality of life. I
don't see that that is being preyed on. I may be wrong, but that is what
it looks like.
MS. COLE: Well, again, if I can use
my analogy of elderly people who have the hope of having their roof fixed, say,
people are more likely to knock on their doors because they know that they are
going to be more likely to say yes to a therapy.
DR. WARREN: But we are running to
ethics, though. We are running into the ethics of the practitioner, and
the ethics of the practitioner can't be dictated.
That comes into both ways. If you are
ethical and they need the roof fixed, then they get the roof fixed. If you
walk in and you are not ethical, I don't care if they have got a brand new roof,
it needs to be fixed. That happens in all professions. It is not
just in CAM. It is in conventional medicine, it is in conventional
dentistry, it is in every single aspect of our society today.
I am not going to argue, but -- yes, I am.
MS. COLE: My intention is not to do
that, either. Our point in this really has more to do with, yes, when
patients lose hope, that definitely plays into what decisions they make,
regardless of what kind of therapy they get, whether it be allopathic or
otherwise. There is no question about that.
I am trying to understand your point, and
thinking that whether you are saying, don't you think that happens in the
medical world as well. Possibly, it does, but wherever it happens, we want
to make sure that our patients get the right information about what works and
what doesn't. If they choose, still, to use it, that is their right.
Again, it applies to both worlds. We
are talking about complementary and alternative medicine here today, and so that
is why we say it in relation to that today. I really am not disagreeing
with what you are saying about it happening in the other worlds as well.
DR. WARREN: One more question to Ms.
Pittman. yes or no, is the American Dietetic Association feel like they
are the only qualified to use nutritional supplementation in helping people heal
themselves?
MS. PITTMAN: The American Dietetic
Association feels that their members are well qualified to help consumers
understand or incorporate supplements, or other nutritional complementary
medicines, into their plan.
DR. WARREN: Are you specifically
trained in the use of dietary supplementation?
MS. PITTMAN: Many members of ADA are
specifically trained in the use of dietary supplements. We have a Dietetic
Practice Group.
DR. WARREN: But not everybody.
MS. PITTMAN: Not across the
board. There are specific practice groups.
DR. GORDON: Wayne, go ahead.
DR. JONAS: Candace, can you give us
an idea of where access is on the Hill. Is the support growing for
it? Is there a critical mass? Is it being attached to anything
else? What is the likelihood that this is going to get looked at this year
in a serious way or be addressed?
MS. CAMPBELL: We have been promised
that this is our congress. We have been waiting for six years,
patiently. Other things like Medicare reform and FDA reform were way ahead
of us.
We have always enjoyed very strong
bipartisan support. It has never become a partisan issue. My
reaction is, based on what we have heard from the Bush Administration and HHS,
to date, that it is no longer a hostile environment, where it was under the
previous administration.
So I am very hopeful that if we make a full
court press on the bill in this congress, that it will get very serious
attention. I don't think it is the kind of bill that would stand on its
own, but there are so many health bills moving, that it would probably be
attached to something that looks like a must-pass vehicle.
DR. JONAS: The Bill of Rights, is it
all related to that?
MS. CAMPBELL: Well, we probably
should have called it that, but we didn't. They got it first. I
don't know, I think the Patient's Bill of Rights is so controversial that they
would hate to add an anchor. The Access Bill will be controversial on its
own, so they will probably attach it to something less heated.
DR. GORDON: Linnea, and then Joe.
MS. LARSON: My question is kind of
speculative in nature, and so any of you who wish to comment. It is not
quite formulated.
One of my concerns, really, is the
medicalization of culture. I don't want to go into an art museum and think
that that is my daily dose of art. I want to be able to go into an art
museum to have the experience of art, or, listening to Bach, I am listening to
Bach, not with the express purpose that my immune system is going to be
bettered.
My question really is a philosophical
question. Perhaps we can say those who use these specific modalities
within a medical system, allopathic or whatever, we could consider being
reimbursed, but I am really questioning whether or not all of culture is being
put to the test of simple medicine.
MS. SIMPSON: In responding to that, I
do think there is a place, obviously, for the arts for our own aesthetic
pleasure and for our own benefit and growth, personal, social, emotional.
When it comes to the application of music therapy, however, I look at it
separately because your goals are non-musical. The goals are not music as
an end, but music as a means to get to the end, music as a means to effect a
change behaviorally, emotionally.
So it is applied in a different way than
the "therapy" you might receive in going to a concert, or the benefit or
aesthetic pleasure that you have from that experience, because I do think that
is something that we all need to have in our lives, but it is a separate aspect,
and different from the application of music therapy in a clinical setting.
MS. Di MARIA: I work with severely
emotionally disturbed children here in the city, and a lot of them, because of
their difficulties have trouble verbalizing their concerns. Most of them
love art therapy. One five-year old with whom I work calls it art thirsty.
So they come, and it is easier to make a
picture of something that is going on at home or someone being bullied in the
classroom -- well, hopefully not the classroom, but in the neighborhood,
wherever -- and then we can talk a little bit more easily about it by talking
about what is going on in the picture.
DR. GORDON: Joe.
DR. PIZZORNO: Candace, I would like
to thank you for the fantastic work you have been doing here in Washington to
improve health freedom. It has been really quite impressive.
MS. CAMPBELL: Thanks.
DR. PIZZORNO: You made some fairly
strong statements about the FDA, and I would like to ask your opinion on
something. We have been discussing suggesting to Congress to create a new
branch of the FDA to regulate nutritional medicines or dietary supplements,
whatever term you want to utilize, for this.
Would you comment on what might be the pros
and cons of such an action?
MS. CAMPBELL: I don't think there is
any fixing the FDA when it comes to this. I would certainly like to look
at a proposal that recommended a separate way to address natural products.
I wouldn't put it at FDA. It is a little bit like putting the Office of
Alternative Medicine at NIH. You can do it, but it is putting them right
in there with the sharks. So I think it may be the only solution.
I believe Canada has done this recently,
with a separate branch that handles natural products. Maybe they haven't
done it long enough to give us any kind of a track record, but I wouldn't put it
at the FDA. I don't think that they are capable of changing this very
entrenched bias against nutritional products. It is really not a system
that can be fixed. They are not willing to fix it.
DR. GORDON: I have two quick
questions. I think they are quick. The first is for both of you,
both Audrey Di Maria and Judy Simpson.
You spoke about research funding. Do
you feel that the access to funding is not currently adequate? I mean the
access, not the funding.
MS. SIMPSON: No. In fact, it
seems like the methods to getting to that access, getting to those funds is very
difficult. It has been, perhaps, related to the fact that our cadre of
researchers is not large enough -- or, well-trained researchers to do the
quality research.
I know that there a lot of therapies out
there attempting to increase our amount of research, but they may not be
adequately trained in doing the appropriate type that we need to affect
reimbursement issues.
MS. Di MARIA: I will agree with that,
that up until the past 10 years, we really didn't have a lot of research courses
in the training programs, and we are trying to rectify that.
DR. GORDON: One of the things that we
heard earlier today -- I don't think that you were here earlier when Nancy
Pearson and Neal West from NCCAM spoke -- is that they have programs to train
researchers, and they have research fellowships. I think that you ought to
look at the NCCAM website and speak with one or the other of them about those
opportunities, because they are interested in expanding it to all the different
health/mental health professions.
MS. SIMPSON: I know we had
communications with AHRQ in the last year and a half in looking at what
opportunities, in particular music therapy, in accessing some of the funds that
they have for research. So it has been a process, but it isn't something
that we have had success with yet.
DR. GORDON: My suggestion would be
you speak to them and you talk with them, and speak to them about your
concerns. Let us know how that goes, because I think it is very clear that
they are trying to reach out to provide research training to the entire field,
and that you would certainly qualify.
Candace, I wanted to ask a question, which
may or may not be quick. I wonder if you could elaborate just a little bit
more on your concern about DSHEA, because I gather what you are saying is the
provisions are there in DSHEA but they are not being adequately implemented.
If you could just give, real quickly, a
couple of examples of how that is, just so that we can begin, and then maybe
later on we can speak with you more about getting more information.
MS. CAMPBELL: Well, you probably know
that the big debate, when DSHEA was being considered, was whether and how to
allow health claims. Congress clearly wanted there to be an increase in
the amount of information provided about supplements to the American public.
The bill was jammed down the throat of the
FDA, and they have spent all the ensuing seven years trying very hard not to
abide by that. One of the ways they have done that is with their
Significant Scientific Agreement standard, which is never defined.
We are not allowed to have cops pull us
over for speeding when the speed limit is not posted. So if you don't have
a standard by which to judge health claims, none of them are ever
approved. So that was the gist of our court case. We didn't think it
should have been necessary because it was clear in DSHEA, but the Agency was not
abiding by the will of Congress or the law.
I can give you a perfect example.
Folic acid health claims, as they relate to the prevention of neural tube
defects. That is a no-brainer. I think it has been about 12 or 13
years that CDC has been publicizing that. Doctors have been telling their
patients this for years. A year or two ago, the FDA even encouraged food
manufacturers to supplement bread products with folic acid. They would not
allow a health claim for folic acid on dietary supplements.
It is like a Kafka novel. First, they
refused our health claim outright. They said no. Second of all, they
said, not only was our health claim so misleading, that there was no way it
could be rendered non-misleading through the use of a disclaimer, when the
Pierson decision specifically said the FDA must allow the use of disclaimers.
So, in other words, if you said 7,000
studies seem to show increased intake of vitamin E improves your cardiovascular
health, that would be a health claim. If the FDA said, that is not enough
proof, they would have to let you say, this has not been proven conclusively,
or, this has not been approved by the FDA. Still, the information is out
there, but it doesn't have the imprimatur of the FDA.
They said there is no way we could make a
health claim about folic acid, non-misleading, with a disclaimer. So we
had to sue them again. Then they said, okay, but you can't say that
supplements are more effective than folic acid found in foods in common form,
when all the science has been done on supplements.
Then they said, all right, but you can only
say up to .4 micrograms. We wanted to say .8, because .4 gives you
something like 80 percent effectiveness, .8 is nearly 100 percent
effective. So we thought, why not tell women .8. We are not costing
them millions of dollars here, we are talking about 12-, $15 a bottle.
The FDA fought us at every step of the
way. Then they said, okay, you can use .8 micrograms, but you have to use
it with a disclaimer that we write. Their disclaimer was about 150 words
long and it didn't reflect the science. You couldn't fit on a bottle and
it was wrong.
Finally, we won. The judge said, in
her decision, that she felt that either the Agency was intentionally trying not
to abide by the Pierson decision, or they were stupid.
DR. GORDON: Thank you for giving us a
feeling for some of these issues. I just wanted us to get a little glimpse
at the whole health issue.
Thank you all very much.
[Applause.]
DR. GORDON: Good afternoon.
Nancy Haller.
MS. HALLER: Thank you for allowing me
to speak today. I am with the Feldenkrais Guild of North America, and we
are as diverse on this subject as there are practitioners, so I will give some
viewpoints as to what might bring more consensus to our community.
There is an enormous need in our country to
have a statement defining what is health. We are working to add to the
burdened systems without an overall statement that gives some structure to light
at the end of the tunnel. When a public statement of health is made, the
programs, people, and products necessary to meet the statement to fulfill the
outcomes are made available.
Language will be vital to this process and
needs to be inclusive and powerful. Looking into the future and
understanding it will take a century of generations to change the overall health
of this nation, there is no better time to begin than now.
Once there is a statement for people to
hear, see, and think about, then gradually there will be an action to meet the
concepts and bring the reality to life. We all hear the statements
contrary to our health in our daily lives and we have followed them.
Advertising has made catch phrases that we can recite, and when it comes to the
place of making choices, they ring in our heads and influence our decisions.
It is possible to use these same concepts
to the advantage of people in relationship to their health. Achieving
health across the nation is a broad subject that requires allopathic,
alternative, folk medicine, spirituality, environment, research, education, and
cooperation. There are models where all of these have a place and are
deemed appropriate and necessary.
Education and trust are paramount to begin
this ongoing change in the whole structure. We need a campaign that begins
in multiple directions, coming from a stated mission for health in this
country. The ultimate goal is survival.
This is a long-term program that needs to
be addressed. Within the structure is a place for everything that is
involved in creating a healthy society. It is understandable that there
would be opposition to this concept. Many huge corporations have made
billions supporting our unhealthy lifestyles.
Short-term needs for health include
creating the programs to fill the needs of people in prevention and care,
education and accessibility to the programs by the people, trained professionals
to work on many levels of care as the needs arise, and options for payments that
are affordable and will allow profits to the insurance companies.
We are headed in a direction that is
appropriate, yet it seems to be scatter-shooting into the dark. There is a
need for empowerment of people to trust that they are the ultimate physician,
and we as practitioners are here to listen and to aid in their health decisions,
offer directions for appropriate services and recovery.
As practitioners, we have the obligation to
be educated, informed, cooperative, and able to hear the request and to aid the
client with their choices, suggest appropriate treatments or services and
products. We have the need to have insurance coding that will accurately
define the work or product that is provided.
The insurance companies require that
accurate billing is done, and then they are responsible to ensure that the
practitioners have timely payments for services rendered. Acceptance by
the public that they hold a portion of the payment responsibility, also allows
them to participate more fully in the ownership of their health and well-being.
Finding appropriate avenues for ease in the
acceptance of death will also be a portion of the work that is necessary for the
future. The circle is possible.
DR. GORDON: Thank you.
MS. HALLER: You're welcome.
DR. GORDON: Julie Merrill.
MS. MERRILL: Good afternoon,
Commissioners. My name is Julie Merrill. I am an Oriental medicine
practitioner, a board member of the American Association of Oriental Medicine,
and the vice president of the Maryland Oriental Medicine Association.
The AAOM is the oldest and largest national
organization for acupuncture and Oriental medicine professionals. Thank
you all for your hard work and for this opportunity to comment.
Let us return to the topic covered
yesterday and Monday, CAM coverage and reimbursement. Do you see this New
York City subway token? Do you see the hole in the middle of it? The
hole in the middle of the token represents inadequate coverage. Proper
coverage for services provided by properly trained practitioners can fill that
hole by providing broader access to health care that actually has the potential
to provide savings to the federal government.
Federal programs and private insurance
companies must reimburse for Oriental medicine's full scope of practice.
Acupuncture as well as moxibustion, herbal therapy, manual therapy, nutritional
counseling, et cetera, in conjunction with our diagnosis, evaluation and
treatment planning at each office visit.
These treatments replace and reduce other
more costly health care expenditures. This coverage should be mandated as
a means to reduce the need for costlier interventions.
As for the analogy of the token, Oriental
medical professionals are concerned about tokenism of various discount programs
being fraudulently marketed by health plans to appear as a premium
benefit. Such token attempts can be replaced by broader based health care
industry mechanisms like the ABC insurance coding system developed by
Alternative Link, discussed in yesterday morning's panel.
While there are currently two CPT codes for
acupuncture, a more complete coding system, such as that developed by
Alternative Link, would not only aid in the equitable reimbursement of Oriental
medicine and CAM services, it would also improve tracking ability and further
outcome research.
Other initiatives are also underway.
AAOM supports the Hinchey bill that would provide coverage of acupuncture to
Medicare patients and federal employees. AAOM also supports continuation
of the personal Medical Savings Account insurance option as a way to cover
preventive health care services.
The hole in the center of the token also
represents a gap in the logic that better-trained practitioners are paid less
than those who are less trained. A practitioner with a masters or a
doctorate in Oriental medicine has the ability to make an individualized
differential diagnosis to more specifically and effectively treat a patient than
someone who has training in a completely different form of medicine who
subsequently studied Oriental medicine for 200 hours. Thank you.
DR. GORDON: Thank you.
Su Liang Ku.
MR. KU: Good afternoon,
Commissioners. My name is Su Liang Ku, with the Florida Institute of
Traditional Chinese Medicine. I would like to focus my testimony on
traditional medicine, or TCM, particularly.
Currently, there are many patients,
especially those poor senior citizens who do not have access to TCM services and
products because the TCM practice and products are not covered by Medicare or
their health insurance. This has greatly diminished their patient's
privilege to assess TCM care and interventions to benefit their health.
In order to protect the health and
well-being of our citizens and to make this form of medicine more accessible,
and at the same time, to reduce overall health care expenses, additional federal
and state law and policies need to be established to better recognize TCM in the
following format:
Number one, TCM be recognized by federal
and state laws and policies as a form of standard medical practice; (B) TCM
services and products be adequately covered and reimbursed by all the federal
and state programs and private health care coverage systems; (C) all federal-
and state-funded health care programs or facilities be urged to provide quality
TCM services and products to all patients who seek them.
The reasoning is, number one, TCM is
utilized by approximately 40 percent of the Americans, and TCM is a well
established, well documented, and complete medical system that has been
practiced for thousands of years on billions of patients; (B) TCM is effective,
safe, and economical; (C) TCM practice is well regulated by state regulations.
The access to safe and effective TCM
practice may be improved by adapting clear policies defining the qualified
providers by requiring one or more of the following:
Number one, National Board or NCC
certifications; (B) licensed by the State Board of Acupuncture; (C) a minimum of
four academic years, with a minimum of 150 semester credit hours of training.
It is important to recognize that TCM is a
complete, yet unique, medical discipline. Over 30,000 medical texts
exist. This body of knowledge cannot be learned in a couple of hundred
hours, or by a non-residential training.
In the past 30 years of TCM practice in the
U.S., a very few malpractice incidents of acupuncture and herbal medicine.
Most were caused by practitioners other than those who have received adequate
training, or who were licensed by the State Board of Acupuncture or certified by
the National Board. Thank you very much.
DR. GORDON: Thank you.
Sandra Chase.
DR. CHASE: Good afternoon. I am
Dr. Sandra M. Chase, the immediate past President of the American Institute of
Homeopathy, the nation's oldest national medical association, and a former
President of the National Center for Homeopathy, the nation's largest public
organization representing the interests of classical homeopathy.
I am a family physician in the private
practice in Fairfax, Virginia. I am here to share with you our concerns
for reimburse, in general, and via Medicare, in particular.
Homeopathy is unique in the regulatory
status among CAM modalities. Specifically, homeopathy is included in the
1965 Medicare Act and the Homeopathic Pharmacopoeia was recognized in the 1938
Food, Drug, and Cosmetic Act. This places homeopathy drug products under
ultimate regulatory authority of the FDA, which in 1988, promulgated the
Compliance Policy Guide for the regulation of their marketing.
Homeopathy physician visit, which range
from a few minutes for a simple acute case, up to two hours in length for a
complicated chronic case, may be billed under current E&M codes, using the
time component, where more than 50 percent of the visit involves consultation
rather than physical examination. Codes for additional time may be added where
the visit exceeds 60 minutes, or, alternatively, some physicians ask that the
patient return for a second visit in order to complete the homeopathy
case-taking process.
The keyword search for "homeopathy" on the
website for Local Medical Review Policies, referenced by Dr. John Whyte of HCFA
earlier this week, reveals that only New York policy M-95-3 bans homeopathy
among other alternative medicine from Medicare coverage.
This suggests that homeopathy is covered by
Medicare elsewhere in the United States. Incidentally, the language of the
New York policy inaccurately describes homeopathy as including therapies using
such products as antioxidants, oxidizing agents, cellular and chelation
therapies, and hydrogen peroxide.
Nonetheless, physicians employing
homeopathy have been harassed by HCFA in several states. The threat of
that occurrence, along with the increasing complexity of E&M coding, and the
potential punishments for miscoding, have caused many homeopathic physicians to
opt out of Medicare participation.
The end result is limited access to
homeopathic medical care among the elderly and the disabled, the very
populations in which pharmaceutical costs are skyrocketing and the most
potential cost savings could be achieved with medicines that cost pennies a
dose.
We recommend two actions. First, a
Medicare statute should be enforced as a national policy, allowing physicians to
practice homeopathy without fear of reprisal throughout the 50 states.
Second, when that is accomplished, we
recommend the addition of a two-digit suffix to the E&M CPT code, indicating
homeopathy has been used, by which mechanism would facilitate tracking of the
utilization and cost effectiveness of homeopathic medical care throughout the
health care system. Thank you.
Panel Discussion
DR. GORDON: Thank you very much.
Questions from Commissioners? I have
just a couple. I want to say that I appreciate the testimony you
brought. I especially appreciate Sandra Chase and Julie Merrill for
picking up on our discussions, and coming back and helping us look at thing a
little bit more deeply.
I wanted to ask you, Dr. Chase, about the
whole issue of HCFA prosecution -- I am not sure what it is -- the adverse
interactions between HCFA and homeopathic physicians. Can you tell us a
little bit more about that, what happened?
DR. CHASE: Yes, sir. I can give
you two specific examples. A colleague of mine in Virginia, several years
ago, was told by the local oversight body that manages Medicare that they would
not cover his Medicare patients. The then president of the American
Institute of Homeopathy wrote on behalf of this physician and showed the proof
that homeopathy is included in the Medicare Act, and so this physicians patients
were able to be covered.
However, another colleague, more recently,
who is located in the State of New York, was also audited on the same level and
was provided with the same information that was provided in Virginia, and the
regional authority said, well, that doesn't matter; we are not going to have
homeopathy covered in this area.
Additionally, I can give you the
information that in my own practice, I had a patient move from my state to New
Jersey, and in writing me a note, mentioned that she, who is a Medicare-eligible
patient, was not able to have her homeopathic care covered now that she was
living in the State of New Jersey.
DR. GORDON: Thank you.
Yes, Ming.
DR. TIAN: Since we have two experts
of CAM practitioners regarding using herbs, I have a question for you. Do
you have any recommendations or suggestions, how do we ensure patient's safety,
and also the benefits from the herbal remedies? And how do we regulate
from the government point of view?
MS. MERRILL: Two things are happening
within the Chinese herbal medical community. The American Herbal Products
Association, AHPA, in conjunction with the five major Oriental medicine
associations, are taking it on themselves to put together a book, a botanical
safety handbook.
It is going to be three or four years in
the making, where they are going to be looking at many authoritative resources
regarding toxicology and other concerns, and to provide that to federal
regulatory agencies to help in their decision-making process.
Also, the American Association of Oriental
Medicine, I happen to be at the chair of the Herb Committee, and we are putting
together an herbal safety course and manual for all students who will be
graduating from school that is analogous to the current Clean Needle Technique,
which is a requirement before students start their clinical rotations.
MR. KU: I would like to present this
in a different perspective. Just like the Western medicine, it has to be
practiced by qualified practitioners, just like prescription drugs have to be
prescribed by duly licensed practitioners. As neurological surgery, open
heart surgery has to be performed by a qualified surgeon, so does Chinese
medicine.
There is 100,000 items in our compendium
and 100,000 formulas in the compendium. It requires a tremendous amount of
study. It cannot be practiced by someone who has a few hundred hours
training. The only way to secure public safety is to regulate it
accordingly, to allow only the qualified practitioners who prescribe that.
Banning it is not an answer, just like you
cannot ban open heart surgery because somebody died under open heart
surgery. Down to the point is, who is qualified to prescribe it.
That is my recommendation.
DR. GORDON: Thank you.
Wayne.
DR. JONAS: I have a question, first,
to Dr. Chase, and then to Mr. Ku and Ms. Merrill, a kind of a
flip-side-of-the-coin question, if you will.
What is the position of the National Center
for Homeopathy on lay practitioners, and what is their role, in homeopathic
practice, on non-physician or non-licensed practitioners? Are they
qualified; should they be able to practice, this type of thing.
The flip side. What is the position
of traditional Chinese medicine groups on M.D. practitioners from this country
who do not get full training in Chinese medicine? Should they be allowed
to practice; are they properly trained.
If you want to go second, or first, or
whatever, it doesn't matter to me.
DR. CHASE: I am a member of the
American Institute of Homeopathy and a former officer in that. I am a
member of the National Center for Homeopathy. I am no longer an officer
there. I really can't speak to that they have an official policy in regard
to lay practice.
I am not aware that they have an official
policy about it. They publish a resource guide that lists people, but I
don't think they take a stand that they are advocating non-licensed people
practicing.
DR. JONAS: Isn't there isn't a
training program? I know there is in England, the Society of Homeopaths,
but isn't there one in the United States that is attempting to develop a fairly
extensive course for training non-M.D. homeopaths?
DR. CHASE: There are a number of
training programs that have come to the U.S., primarily from the United
Kingdom. Again, I am not particularly familiar with the ins and outs of
these organizations. They do pattern themselves after the Society of
Homeopaths, where under Common Law, it is legal for them to be doing what they
are doing.
In this country, the one area that I know
that they have had some success in their attempts, is, I believe, in Wisconsin,
where they recently got a law allowing them to practice within that state.
I don't know the particulars about that.
DR. JONAS: Do you feel like there is
a role for lay practitioners in this mix somewhere? Or, do you think
everyone should be a fully qualified physician, licensed physician?
DR. CHASE: Which hat do you want me
to wear?
DR. JONAS: Take your pick.
DR. CHASE: I think that people should
be appropriately qualified in all ways to be providing health care for the
public.
DR. JONAS: Dr. Ku?
MR. KU: I am not currently any
officer from any national association, so I do not speak for them, but it is a
general consensus in our profession, as well as I am running a school, that
herbal medicine should be diagnosed by TCM practitioners.
Seventy percent of them are very neutral
and very safe. They can be taken for a certain length of time by the
public upon diagnosis, but one-third of them are very potent and have side
effects. They cannot be taken too long.
So therefore, we do not recommend the
public taking herbal medicine without any consultation to any practitioners, nor
do we recommend anybody who has less than adequate training, starting to fool
with this. Just as I can read a PDR, do you want me to prescribe Western
medical drugs to the patients? You don't want that. That is my
position.
MS. MERRILL: The physician's course
is very abbreviated. It is a 200-hour course. Sometimes they go on
to do some further study, but most of the course itself is distance
learning. They do learn trigger point therapy, some simple musculoskeletal
treatment, and they can, sometimes be effective in the point-and-shoot variety
of acupuncture.
However, they are not trained in internal
medicine, in differential diagnosis, like my colleague, Dr. Ku, mentioned, nor
do they know the whole field of herbal therapy, which, as Dr. Ku explained, is
very intricate, very complex, very elegant, and very important to reinforce the
acupuncture treatments themselves. They are often used in combination in
China, and have for thousands of years. They do other adjunctive
therapies, such as cupping, manual therapies, like soft tissue manipulations and
guasha.
DR. JONAS: In other words, I get the
sense from all of you that only fully qualified, you feel like, should be
allowed to practice these therapies.
MS. MERRILL: Yes. I can speak
for myself and the American Association of Oriental Medicine, that we feel that
they are not qualified to practice the full spectrum of Oriental medicine.
MR. KU: That is our general
consensus, across the profession, that the recommendation for the practitioners
is to adopt a national standard, which takes about four academic years and no
less than 150 semester credit training, including the herbology and so
forth. Those are our recommendations, and most of the state regulatory
boards also adopt that policy, and that is how they are given their licensure
exam standards.
DR. CHASE: Wayne, I would just like
to make the point that the groups that you mentioned in regard to the North
American Society of Homeopaths is a separate organization affiliated with
neither the American Institute of Homeopathy, nor the National Center of
Homeopathy.
DR. GORDON: Effie, do you have a
question?
DR. CHOW: Yes. Building on that
question, is there any attempt of communication between the lesser training and
the more extensive training versus the physician and the lay homeopaths?
Any comments on that? Do you feel that communication between the groups
would help any?
MS. MERRILL: I don't know the full
history between the two groups, but I know that there has been a lot of
disagreement because the agendas are very different.
DR. GORDON: Thank you all very
much. We appreciate it.
[Applause.]
MS. CHANG: Our last panelists, very,
very patient. Thank you very much. Edward Owens, who is a
substitute, Matt Russell, Carolyn Sabatini, Christina Walker, and Alan Dumoff.
DR. GORDON: Edward Owens, please.
DR. OWENS: Thanks for allowing me to
speak today, and especially, thanks to Veronica for inviting me to come and
slipping me into the schedule. I am going to go ahead and read my talk.
I am here to discuss some of the challenges
we face in the chiropractic research community, and reiterate what some of the
other speakers for chiropractic have said. I am the research director at
Sherman College of Straight Chiropractic in Spartanberg, South Carolina. I
have been involved in chiropractic as an educator, a research, and practitioner
for almost 20 years.
My boss, Dr. Brian McAuley, spoke here on
February 23rd, and he raised some very important points. He was speaking
for chiropractic, but really CAM in general. First, there is a huge
disparity between the research funding to medical schools and that to
alternative schools.
The NIH alone granted some $6.5 billion to
the top 50 medical schools in 1999. However, the entire budget for the
NCCAM, which funds most of the CAM research, which is the federal funding arm
for CAM research, is on the order of $70 million, only about 1 percent of the
NIH budget.
The chiropractic groups draw from the CCR,
which is funded by the NCCAM, and they have funded about $250,000 of research in
the last four years. We need to formally recognize the value and
appropriateness of the meta-therapeutic health care paradigm that focuses on
enhancing performance and function, rather than treating disease, at the risk of
making you all complemental.
This would put more emphasis on the
complementary in CAM, and recognize there is a fundamental difference in the
approaches between allopathic care and complementary care. Complementary
care is more often aimed at improving the health of the whole person, rather
than treating a particular symptom. You might even have people going to a
complementary practitioner, even if they feel well. They want to prevent
any kind of illness in the future.
Point three. More federal funding
should be directed to research efforts in the wellness and preventive health
paradigm that explores ways to help people avoid serious health problems and
enjoy greater function and performance. This emphasis is a natural
outgrowth of an increased awareness of the potential of meta-therapeutic methods
to help forestall disease.
Drs. Tony Rosner and Bill Meeker spoke
here. They are both chiropractic researchers. Some of their points
were aimed at helping to solve, to reach some of the goals that Dr. McAuley
raised. Dr. Rosner again brought up the idea of preventive aspect of
chiropractic care, particularly the effects of long-term care.
We won't really have RCTs that can
demonstrate effects of long-term care. We have to have different types of
studies. An emphasis on randomized, clinical trials to test the efficacy
of any therapy on a particular condition would not be effective in supporting or
refuting the preventive benefits of long-term care. We need to relax the
dependence on RCTs, and perhaps open research funds to long-terms descriptive
studies such as cohort designs and case series.
We tried to do some of this at Sherman
College, and we found that federal funding on this kind of research is very
difficult to obtain, even through our own consortial Center for Chiropractic
Research. Dr. Rosner suggested that we could provide better balanced and
enlightened study sections to review grant applications throughout the NIH, but
we could also apply that through the CCCR. Thank you very much.
DR. GORDON: Thank you.
Matt Russell.
MR. RUSSELL: Chairman Gordon and
remaining Members of the Commission, good afternoon. My name is Matt
Russell. I am the executive director of the National Integrative Medicine
Council.
There are many important issues about which
I could testify today. As you know, just a little over a week ago, the
Integrative Medicine/Industry Leadership Summit convened in Arizona to address
issues concerning reimbursements, clinics, employer strategies, CAM integration,
and national policy.
It was very heartening for me to see such
positive communications across stakeholder lines. While we honor all the
good work coming out of this summit, and expect to play an integral role in
advancing issues of importance to the CAM professions, my testimony today
focuses on specific public policy recommendations for physician education.
This is an area where we believe an immediate opportunity exists.
Not surprisingly, the current structure of
education and training of physicians in this country is inadequately preparing
our physician workforce to meet the needs of patients. I believe it was
Hippocrates who is often quoted as saying, "Cure sometimes, heal often, comfort
always."
Unfortunately, today's physicians are
encouraged to cure always, heal if they have the time, and leave the comforting
to someone else. Physicians are entering practice with frustrations about
not being able to spend more than just a few minute with their patients and are
forced to rely too heavily on costly and impersonal technologies.
Ironically, the shift toward high tech
medicine over the past few decades is a dramatic departure from what our
patients are saying, loud and clear, is important to them. Patients are
looking for doctors who are sensitive about complementary and alternative
therapies, and can knowledgeably guide their patients through the confusing maze
of treatment options.
So what, then, can be done to respond to
this appeal for a healing-oriented health care system without neglecting the
significant role that conventional medicine plays. There have been many,
many solutions proposed. We have heard that our case needs to be made to
the insurance industry, once issues of cost effectiveness and quality can be
ascertained.
We have heard that the case needs to be
made to employers that if our nation's workforce unites behind this message,
then third party payers will respond. We have heard that the solution lies
in more appropriate moving away from the RCT, and toward a clinical outcomes
research. We have heard the consumer and health care providers alike need
access to reliable information about choices in health care.
These are all very important issues, each
playing a significant role. However, if we do not have an adequately
trained and educated physician workforce, then our model system is still
threatened.
It is ambitious, if not unrealistic, to
assume that we can realize the kinds of shifts in medical education that we
believe is important over the short term. However, with only a few years,
we can begin to see the initial effects of this model.
Here are my recommendations. The
National Integrative Medicine Council is advocating for a small federal
demonstration program to gauge the effectiveness of building pre-doctoral
medical educational around an integrative model.
The concept of providing grants to medical
schools to evaluate new innovations in education is not new. Launched in
1997, under the Health Resources and Services Administration, HRSA, the federal
UME-21 program, which is Undergraduate Medical Education for the 21st century,
has already awarded 18 grants to 18 medical schools, each of which have proposed
certain curriculum innovations.
We believe a similar system can be created
for medical schools to build integrative curricula. The funding for
medical schools for this purpose is critical, and we urge the Commission to make
recommendations for HRSA to set aside specific monies to encourage medical
schools to train medical students in integrative curricula.
DR. GORDON: Thank you, and thank you
for focusing on a specific recommendation. We appreciate that.
Carolyn Sabatini.
MS. SABATINI: Hello,
Commissioners. Thank you for this opportunity to speak. I am the
government and regulatory affairs manager at Pharmavite Corporation.
Pharmavite manufactures dietary supplements and markets these products under the
Nature Made and Nature's Resource brand names.
Since 1971, Pharmavite has been committed
to providing consumers with quality dietary supplements to make a positive
impact in people's lives. We are pleased to offer suggestions on the
dissemination of reliable information on CAM to health care providers and the
general public.
I will share with the Commission some of
Pharmavite's routine information-sharing practices. We encourage other
dietary supplement manufacturers to continue or adopt similar communication
approaches because information exchange benefits everyone.
Pharmavite regularly shares reliable
information on its products with health care providers. We employ a team
of registered dieticians, traveling the country giving accredited continuing
education courses for pharmacists, as well as science-based lectures on dietary
supplements to other health care providers, professional associations, and
interested consumer groups.
We developed a comprehensive, heavily
referenced product manual that outlines usage, recommended dosage, safety, side
effects, and adverse reactions, if any, with conventional medicines. We
call it our vitamin and herb university, are pleased that the Purdue School of
Pharmacy includes this manual as part of its curriculum.
We have also distributed this manual to
retail pharmacists, nutritionists, and others nationwide. We also operate
several toll free information lines for trained professionals, as well as the
general public, to address any questions about product safety, usage and stated
benefits, and clearly note warnings on our product labels, if needed, and
identify those groups of consumers, such as pregnant women and those currently
taking prescription medication who should consult with a health care provider
before taking our products.
In addition, our website contain detailed
product information, suggested dosage, drug/nutrient interactions, and an
information forum we call "Ask Our Nutritionist."
However, I would like to address one
additional subject. That is objects and barrier, and possible solutions to
accomplishing this goal. One obstacle that we face in the industry is the
inability to effectively communicate product quality to the public.
While Pharmavite and other dietary
supplement manufacturers follow strict quality assurance programs, the public
and media perceive that we are not regulated. This misperception may in
part exist because FDA has not fulfilled the Dietary Supplement Health and
Education Act.
Pharmavite has supported and endorsed, and
long awaited formal GMPs to compliment our own efforts to build public
confidence in the quality and safety of our products. We believe the
Office of Management and Budget has an obligation to give FDA the ability to set
the GMPs that we have been waiting for for seven years. Our industry's
ability to disseminate reliable information would be improved if people had a
better understanding of how closely we are regulated.
In addition, I would just like to make note
that is not in my comments, that in meeting today with Senator Harkin's office,
they will be submitting legislation to amend the tax code to include dietary
supplements as a deductible medical expense. Thank you very much.
DR. GORDON: Thank you, and thanks for
clarifying.
Christina Walker.
MS. WALKER: Thank you, Dr. Gordon,
Commissioners and staff. I am a nurse and I am Director of the Shenk Human
Energetic Institute. In this testimony, I will present a case study and
interweave recommendations concerning research.
A 19-year old female victim of a car
accident is in a coma for 10 days, experiences multiple fractures, hypovolemic
shock, right pneumothorax, and a near-death experience. It takes one year
to heal her physical symptoms. For the next 25 years, she becomes a
chronic pain patient. She goes from physician to physician who cannot find
a reason, physically, for her pain.
On her journey, she comes into touch with
alternative medicine. She starts with acupuncture and the pain starts to
reduce, but she is told she is unable to hold the treatments. She begins
her studies in healing touch to study the chakra system, for she knows her pain
lies somewhere energetically.
She begins to explore her consciousness to
make sense of many different frequency bands she experienced during her
near-death experience. Through this search of her consciousness, she finds
she still disassociates and has not fully reentered her physical body from the
trauma she experienced so long ago. With this realization, she
understands, how could any energetic treatment give her the full results.
Recommendation. During research, we
need to get a sense of where is the person's energy body. For example, the
person may say, I am beside myself, which means the energy body is next to the
physical body.
This may effect results if you mix
population types because the treatment is different. With this knowledge
she has now acquired, she enters a state of prayer to find someone who can teach
her how to reenter her physical body. This search leads her to Austria
with the teacher, Christine Shenk.
During the course of her studies with
Christine Shenk, she is taught and experiences that some parts of the energy
system are closer to the physical body, and others are farther away. So,
which space are we really researching? What levels of space are you
studying in the energy body, for each space has to be studied differently?
Recommendations. You need to know
where you are according to the energy body anatomy. The patient learns to
reenter the body, make peace within herself and to start to feel the
regeneration of her energy system, with Christine Shenk's energy trainings.
Now grounded and clear, she finds out her
entire energy system was smashed in the car accident, which explains why she was
disassociated, in chronic pain, and energetically unable to hold any form of
alternative treatment. With this information, she realized she needed to
take a closer look at selection criteria.
Recommendations. Researchers need to
understand the energy anatomy in a more comprehensive way. They need to
see the big picture, not just the small area they work in, because that small
area affects the entire energy system. The client I present to you today
is me. I give much more in-depth recommendations in the paper attached.
Research is based on science, and the
perception of the energy body is based on feelings. Therefore, our study
designs need to be different. Sometimes we are chosen to walk this journey
personally and experience research from that place, which yields a different
knowing.
DR. GORDON: Thank you. Thanks
for the additional testimony you provided for us as well.
Alan Dumoff.
MR. DUMOFF: Thank you, Dr.
Gordon. Thank you, Members of the Commission and staff. I am an
attorney who has been practicing for 13 years, specializing that entire in the
legal and other issues regarding the practice of complementary and alternative
medicine and this integration. I would like to share, just briefly, five
points of concern to focus the attention of the Commission on some
recommendations regarding reimbursement policy.
The first of these has to do with medical
necessity and standards of care in reimbursement decisions. As I know the
Commission is aware, often when insurance companies deny coverage for CAM
practices, particularly with physicians, their stated basis for rejection is
that they are not medically necessary.
What I would like to also focus the
attention of the Commission on, though, is that this rubric is often used beyond
that to actually, in some way, harass physicians who practice alternative
medicine.
In one case I was involved in with a well
known alternative cancer therapist/physician in San Diego, Medicare actually
moved to exclude a physician from participating in Medicare, because in their
view, non-standard medical practice is, by definition, substandard medicine, and
that legal issue really goes to the crux of many of the difficulties that we
face in this field.
In another situation, a physician I
currently represent in Maryland, he got brought before the Board because Blue
Cross, who was concerned about the innovative practices he was providing,
complained to the Medical Board, even though he was not submitting bills for
what he knew were non-covered services. So even if you try to practice
legally and bill properly, you can still get in trouble because of differences
of professional judgement.
So I think it is imperative that the
Commission look at medical necessity and standards of care, and the way they
operate across the board in terms of medical reimbursement, and also, the way
medical boards interpret private practice.
E&M coding, the Board has heard a lot
about that. It is very difficult for holistic physicians who spend much
time with patients to properly bill. I would simply urge that the
Commission consider some communication directly with the AMA, HCFA committee
that works on documentation and billing guidelines.
A third issues is Medicare same-day rule,
where if you go see a physician in a practice for low-back pain in an
integrative practice, and then go see the chiropractor the same day, you can't
get covered for the chiropractor. It makes team practice very
difficult.
Fourthly, incident to billing is an issue I
have raised with the Commission in an open letter I had published. I would
just take this moment to highlight the issue. It is one where upcoming
changes could make it more difficult for nutritionists and other practitioners
to bill under a physician.
Fifthly, getting good information is very
difficult. I go into a lot of practices, integrative practices, and the
wealth of details that are involved in properly coding are very difficult for
folks to understand. Some kind of a clearinghouse would help. Thank
you.
Panel Discussion
DR. GORDON: Thank you, and also thank
you for the articles that you have written on the subject.
Questions from the Commissioners?
Veronica.
DR. GUTIERREZ: I have had several
conversations. This is in regards to chiropractic research. We have
17 colleges, we have a consortium for chiropractic research, which has only five
members. So far, all the research dollars have been directed directly to
this group, and I understand some of that is because of the familiarity of
dealing with the same people over and over again.
I know there has been a barrier to your
college as well as others, and I would like you to tell us if there have been
any other barriers that you have run into in your efforts to get research
dollars.
DR. OWENS: That is one of the major
ones, because that is our major key into NCCAM funding. So going through
the CCCR is our major route there. Most of the problem is inexperience
with the federal forms. That is probably part of it. We don't have
good representation in the review boards of the CCCR. It is mostly
controlled by those five colleges, so we don't have a lot of representation.
Our methods, the straight chiropractic-,
the subluxation-centered care is a little different than the musculoskeletal
methods. The musculoskeletal methods are getting more of the research
funding, and the subluxation-centered does not.
DR. GORDON: Other questions?
Effie, go ahead.
DR. CHOW: Again, regarding
chiropractic. What is straight chiropractic?
DR. OWENS: It is the same as being
subluxation-centered. It is providing wellness care, it is providing
maintenance care that is not directed at illnesses, but more directed at
enhancing function. So it is investigating the spine, looking for
aberrancies in the spine and adjusting those, whether the patient is expressing
symptoms or not.
DR. GORDON: Other questions?
Wayne, go ahead.
DR. JONAS: I had one question to Ms.
Sabatini.
I saw the toll free number in here.
Is it possible to get this report, or is it possible to look at it on the
website, what you are describing? I only have one page in here. I
don't know if there is another one somewhere else. Is it possible to get
more information about this?
MS. SABATINI: About the company?
DR. JONAS: Well, no, about this --
MS. SABATINI: Oh, the Vitamin and
Herb University?
DR. JONAS: Yes.
MS. SABATINI: Yes, it is. I can
provide that. It is not on the website. We have 12 CE programs that
are certified for pharmacists that are on our website that are accessible by a
code given to pharmacists, so that the general public don't access them.
DR. JONAS: Pharmacists can get CE
credit for this?
MS. SABATINI: Yes.
DR. JONAS: I had also one question
for Matt Russell.
Now, HRSA, is there any exclusion in terms
of applying for some of these training grants in HRSA right now? Is it
possible for complementary medicine groups to apply, or for medical schools to
apply?
MR. RUSSELL: Right, the UME-21
program?
DR. JONAS: Yes.
MR. RUSSELL: It is my understanding
that that is only for schools of medicine and schools of osteopathy, and it is
directed just on medical schools. However, there still could be some
opportunities in my written testimony, and the timing of this, Dr. Jonas, is
ideal. Congress is expected to reauthorize the Public Health Service Act,
and the specific titles that fund health professions this year.
So I talk in my written testimony that this
is the ideal framework if we are looking at strategic ways to support and invest
in health professions education, and I mean osteopathic, allopathic, as well as
the CAM profession schools. This is the right time to do it to be a part
of that conversation.
DR. GORDON: Following up on that, are
there integrative medicine programs at medical schools or osteopathic schools
that are being under this act now?
MR. RUSSELL: There are not
integrative medicine programs being funded under UME-21. They are all
about curriculum innovations, but none of them, to date, have been to support a
specific integrative curriculum.
DR. GORDON: If you would, since you
have done this homework, could you send us the information from the bill and
what you would suggest the kinds of recommendations we might make about it.
MR. RUSSELL: Absolutely, yes.
DR. GORDON: That would be very
helpful.
MR. RUSSELL: I would be glad to.
DR. GORDON: Alan, I appreciate this,
perhaps the complexity of this issue related to HCFA, but anything you could do
in terms of making it easier for us to understand the issues. If the
articles have explicated it all, that is fine. If there is anything you
could send us that would help us understand that, because obviously our whole
concern, or the concern of the day and a half of these hearings, has been
related to financing and reimbursement.
So we would very much like to have your
thoughts, both about what the issues are and what kind of clarification would be
called for.
MR. DUMOFF: I would certainly be
happy to provide some more detailed information for the Commission.
DR. GORDON: That would be great.
MR. RUSSELL: Ironically, the nominee
for the new HCFA administrator just had his confirmation hearings this afternoon
on the Hill, so now is a very good time for the community to begin its education
of Mr. Tom Scully, who is the heir-apparent to be the new HCFA administrator.
DR. GORDON: Great. Other
questions from any of the Commissioners?
[No response.]
DR. GORDON: Thank you all very much,
and thank you all in the audience for being with us. Goodnight.
Thank you.
[Applause.]
[Whereupon, at 5:51 p.m., the meeting was
concluded.]
+ + +
CERTIFICATION >This is to certify that the
attached proceedings BEFORE THE:
White House Commission on
Complementary
and Alternative Medicine HELD:
May 14-16, 2001 were convened as herein appears, and that this is the official
transcript thereof for the file of the Department or Commission. SONIA GONZALEZ,
Court Reporter